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Abstract 
The technology of interfacing neurons with machines through implantable neural 
electrodes has significant implications. Although there have been studies implanting such 
electrodes in human to help patients with motor disorders, longevity of these implants 
remains an unresolved issue. One of the key factors influencing longevity has been 
adverse tissue response toward the implanted electrodes 
The objective of this research is to engineer a comprehensive solution that can 
manage the response at the cellular level while preserving the electrode functions. Given 
the complexity of the host response, we hypothesize that a multi-pronged approach would 
better improve the longevity of the electrodes. Specifically, we emphasize the importance 
of modulating the inflammatory response from glial cells and directly protecting neurons 
from oxidative stress induced death. To achieve this goal, a range of polymeric 
therapeutics (i.e., prodrugs) capable of anti-inflammation and anti-oxidation were 
designed and synthesized. These polymers were fully characterized for their structural 
properties and therapeutic effects. Applications of these prodrugs onto the electrodes 
were achieved using the versatile layer-by-layer (LBL) technique, which enabled the 
preservation of electrical properties of the electrodes. These in vitro studies laid down the 
foundations for future in vivo investigations of the efficacy of such a multi-pronged, 
integrated therapeutic approach for modulating host tissue response. Furthermore, the 
synthesized prodrugs can be applied for other types of medical implants, where 
inflammation and oxidative stress are common characteristics of the host response to 
those implants. 
  v
The other approach to achieve therapeutic delivery is the use of stimuli-
responsive polymers. Based on the lower critical solution temperature (LCST) behaviors 
of poly(N-vinyl-2-caprolactam) (PVCL) polymers, its functional derivatives with pH-
dependent LCST behaviors were designed via copolymerization with a functional 
derivative of VCL for smart drug delivery. Sharp and reversible response was observed 
across a broad range of pH values. PVCL copolymer was demonstrated to be non-
cytotoxic at low concentrations. LBL compatibility of the copolymer was also explored. 
The ultimate goal is to correlate the pH-sensitivity of the PVCL copolymers with the 
tissue acidosis phenomenon to regulate therapeutic release. 
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Chapter 1 
Introduction 
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1.1 Neural Interface  
 Chronically implanted recording electrode arrays have the potential to improve 
the quality of life of patients suffering from partial or full paralysis.[1-3] Such arrays can 
be implanted into the cortex of a patient’s brain and the extracellular potentials from 
nearby neurons are recorded, allowing the information encoded to control external 
devices.  
1.1.1 Physical design of neural electrodes  
 Neural electrodes have evolved from glass to metallic materials over the years. 
The dimension of neural electrodes has also been decreasing constantly for the ease of 
handling and minimizing damage to brain tissue, with the help of technology 
advancement, especially the silicon micromachining development. The most common 
modern models include Utah and Michigan type electrodes (Figure 1). The Michigan 
type electrode has been widely used for many years because of its diversity. Hundreds of 
designs and configurations have been developed and these electrodes could be connected 
with the Integrated Circuit (IC) technology, realizing large amount of data collection and 
analysis. The structure of such a micromachined electrode is shown schematically in 
Figure 2. The bulk of the electrode is based on a silicon substrate. The recording sites are 
made from conductive metals such as gold. There is one company focusing on 
developing and manufacturing various types of electrodes for research and clinical 
applications. The size of the recording sites of the Michigan electrode used in our study is 
on the order of micrometer (Figure 3). 
  
 Figure 1. Examples of Utah and Michigan type neural electrodes. (a) Scanning electron 
micrograph of Utah electrode.
electrodes.[5]   
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[4] (b) Various configurations of the Michigan type 
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Figure 2. The general structure of a Michigan type neural electrode.[6] 
  
 Figure 3. Structure of a micromachined single shank acute probe used in our research (16 
recording sites, model: A1×16
 
 
5 
 
 
 
 
-5mm-100-177-A16, NeuroNexus Technologies, Inc.)
 
 
[7]  
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1.1.2 Tissue response to neural electrodes  
Neural electrodes often fail to function reliably in clinically relevant chronic 
settings. One of the proposed leading causes to such failure is foreign body response in 
the central nervous system (CNS), resulting in an encapsulation layer referred to as the 
“glial scar” and accompanied by loss of healthy neurons around the implants (Figure 
4).[8-10] 
The glial scar is formed as a result of activation of astrocytes and microglia. It 
encapsulates the electrode as a physical barrier. It has several adverse effects toward 
normal functioning of the implant. Firstly, this physical barrier is an insulating material 
between the electrode and nearby neurons. The electrical interaction between brain and 
machine is thus significantly compromised.  Secondly, the tight glial scar takes up the 
immediate room around the electrode, keeping neurons away from the interface.  
Neuronal death is another phenomenon that has been considered causing 
malfunction of the neural electrode. Neurons are challenged with a variety of toxic 
environment such as oxidative stress after implantation of the neural electrode. Reactive 
nitrogen species (RNS) and reactive oxygen species (ROS) are classes of free radicals 
and related molecules that are capable of exerting oxidative stress on cells when 
produced in excess. Nitric oxide (NO), a simple yet highly versatile molecule, is a type of 
RNS/ROS frequently studied and involved in a wide range of physiological as well as 
pathophysiological mechanisms. In response to injury, the production of NO can 
overpower the endogenous antioxidants, leading to oxidative stress and cellular damage. 
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Figure 4. Schematic of brain tissue response to an implanted electrode characterized at 
the cellular level.[11] 
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Reactive astrocytes and activated microglia have the capacity to generate NO, and 
the production can be induced by pro-inflammatory cytokines such as interlukin (IL-1) 
and tissue necrosis factor (TNF-α). NO is a ubiquitous second messenger[12] that 
diffuses freely across cell boundaries and can damage neurons by potentiating glutamate 
excitotoxicity.[13]  
1.1.3 Methods to improve biocompatibility of neural electrodes 
Improvements on electrode design[14-16] and manipulation of bioactive 
molecules[17-24] through the tethering and/or controlled release of bioactive molecules 
from the surface are the two main strategies to reduce the aforementioned tissue response. 
Advances in electrode designs include not only microfabrication of electrodes with new 
configurations[25], but also the development of novel polymers at the interface of 
biology[26, 27], and bioinspired, mechanically dynamic polymers to replace currently 
used stiff silicon materials[28]. Standard wound healing suppression and immune-
suppression techniques are options for minimizing the initial immune response and even 
the formation of a glial scar.[8] The available methods of using glucocorticoids and other 
therapeutics to reduce the inflammatory response include systemic administration,[20, 
29] localized delivery from coatings deposited on the electrode surface,[30] and direct 
surface immobilization[11].  However, none of these approaches are ideal. For example, 
systemic administration of drugs may cause serious side effects, including myopathy and 
diabetes, and the presence of the blood-brain-barrier (BBB) adds extra hurdles for 
systemic drug delivery to the CNS.[8, 31-33] Concerns associated with localized delivery 
of therapeutics from surface coatings include the fine balance between drug loading 
 9 
 
capacity and the conductivity of electrode (i.e., potential increase in impedance by the 
coating), difficulty in controlling drug release rate, and the duration of delivery. 
Immobilization of bioactive molecules directly onto the surface of electrodes could 
provide a device with an intrinsically anti-inflammatory surface, but it is still restricted by 
limited potency as the effect is confined to cells in direct contact with the surface. 
Although it is possible that this is a design strategy which can be implemented to control 
the local material-tissue interface while allowing other activated immune cells to 
participate in local wound healing to “clean” up debris caused by electrode implantation, 
this hypothesis needs to be confirmed. 
A potential solution to pharmacologically manage the tissue response to 
implanted electrodes is to enable self-regulated drug release based on the severity of 
tissue response, without interfering with the electrical properties of the electrode.  
Additionally, many studies have used localized release of anti-inflammatory 
agents to control the inflammation against MEAs,[30, 34-37] but few reports have 
addressed direct protection of cells from oxidative stress. We hypothesized that 
protecting cells from the injurious oxidative stress could benefit the communication 
between MEAs and healthy neurons. Astrocytes are one type of glial cells in the brain 
supportive of neuron functions. It has been shown that astrocytes can protect neurons 
from oxidant hydrogen peroxide toxicity.[38, 39] Therefore, we suggest that it is rational 
to shield astrocytes and neurons from oxidative stress associated with implantable MEAs. 
Such an approach could potentially lead to better survival of neurons that are vital for 
long-term MEAs functions.   
 10 
 
1.2 Layer-by-Layer (LBL)  
 Layer-by-layer (LBL) assembly technique is a versatile method for surface 
modification. Traditionally, species with opposite charges are adsorbed alternately to a 
surface, resulting in the formation of thin films with thickness ranging from nanoscale to 
microscale (Figure 5).[40-42] On the one hand, the fundamental underlying mechanisms 
such as the physicochemical aspects are a continuing research area. On the other hand, 
LBL has been recently studied for applications in a range of fields, including biological 
applications such as biomimetics, biosensors, drug delivery, protein and cell adhesion, 
mediation of cellular functions, and implantable materials.[43]  
Though the LBL technique has been most widely applied to charged molecules, 
non-electrostatic forces, such as hydrogen bonding, have been recognized as an 
alternative mechanism for film growth.[44-53] The common hydrogen bonding accepter 
polymers include poly(N-vinylpyrrolidone) (PNVP), poly(acrylamide) (PAAM) and 
poly(ethylene oxide) (PEO), and the hydrogen bonding donor polymers include 
polyaniline, poly(acrylic acid) (PAA), and poly(methacrylic acid) (PMAA).[54] Tannic 
acid (TA), a water soluble natural polyphenol has also been reported as hydrogen 
bonding donor.[55, 56] 
 In addition to sharing the advantages of conventional electrostatic-based LBL 
method, the multilayered-films constructed through hydrogen bonding could undergo 
dissociation upon pH change, which could serve as smart coatings on implants.  
  
  
 
 
 
 
Figure 5. Schematic of the LBL assembly process.
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 from neural electrodes.[45] To overcome this issue, we propose to build a temporary 
drug-containing coating on the electrodes using hydrogen bonding based LBL assembly. 
Upon insertion into the tissue, the layers will quickly disintegrate under physiological pH, 
revealing the underlying electrode surface and thereby eliminating the concern of 
coating-induced loss of electrode functions.  
1.3 Polymeric Therapeutics (Prodrug) 
 Polymer-drug conjugation (Figure 6) is a well-known and widely exploited 
technique that is useful to improve therapeutic properties of peptides, proteins, small 
molecules or oligonucleotides.[57-61] Polymer-conjugated drugs, sometimes referred to 
as polymeric therapeutics or prodrugs, generally exhibit prolonged half-life,[62] higher 
stability, improved water solubility,[63] lower immunogenicity and antigenicity,[64] and 
can be designed to allow specific targeting to tissues or cells.[65] Besides the above 
advantages, in this dissertation, polymeric therapeutics are selected to be compatible with 
the LBL surface modification method to improve performance of the chronic neural 
electrode.  
A wide variety of polymers have been explored for prodrug synthesis. These 
include synthetic polymers such as N-(2-hydroxypropyl) methacryl-amide copolymer 
(HPMA), polyglutamic acid (PGA), poly(ethylene glycol) (PEG), poly(N-
vinylpyrrolidone) (PNVP), and poly(ethyleneimine) (PEI). Examples of natural polymers 
used for this application include dextran, pullulan, chitosan, hyaluronic acid and many 
others.[66] 
  
 Figure 
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In this dissertation, two types of prodrugs were prepared, one anti-inflammatory 
for glial scar prevention and the other anti-oxidative for direct neural protection. The anti-
inflammatory prodrug was built from PNVP. PNVP is a hydrophilic synthetic polymer 
generally known for its biocompatibility and non-antigenicity, and is considered safe for 
biological experiments.[67] Soluble PNVP is one of the most versatile and widely used 
pharmaceutical auxiliaries and topical disinfectants.[68] However, lack of common 
functional groups in PNVP has limited its further applications such as conjugation with 
other biological therapeutics. I proposed to overcome such a limitation by functionalizing 
PNVP with carboxylic acid groups to allow the synthesis of anti-inflammatory prodrugs. 
For the anti-oxidant prodrugs, I prepared a polymerizable monomer derived from an anti-
oxidant and copolymerized it with a biocompatible acrylate monomer with functionalities 
amenable for LBL assembly.  
1.4 Stimuli-Responsive Polymers 
1.4.1 Thermo-responsive polymers 
Thermo-responsive polymers are among the most intensively investigated smart 
materials in biomedical fields.[69-71] A key characteristic of these polymers is that they 
display a lower critical solution temperature (LCST). At temperatures below the LCST, 
these polymers are soluble in water. Upon raising temperatures above the LCST, such 
polymers will undergo a conformational transition from loose solvated coils to compact 
dehydrated globules, collapse and become insoluble in water.[72] Such a phase 
separation process occurs by either nucleation and growth, or spinodal decomposition 
(Figure 7).   
 15 
 
 
 
 
 
 
 
Figure 7. An example of phase diagram for polymers with LCST behaviors.[73] 
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Nucleation and growth are associated with metastability. Spinodal decomposition, on the 
other hand, refers to phase separation under conditions in which the energy barrier is 
negligible, so no activation energy is required. The spinodal line is constructed from the 
points where,  
 

∅ = 0 1 
where G is the free energy, Φ is the composition. 
The binodal curve is related to the equilibrium phase boundary between the single 
phase and the phase separated region. In a binary system, this is related to the chemical 
potentials of an individual component being equal in both phases as expressed by the 
following relationships: 
 ∆ = ∆  2 
 ∆ = ∆  3 
where µ is the chemical potential, 1,2 represent the two components and a,b 
represent the phases.[73, 74] If the temperature of a mixture is raised above the LCST, 
that component undergoes thermally induced phase separation by either nucleation and 
growth or by spinodal decomposition (SD). The minimum value occurring at the 
intersection of the binodal line and spinodal line is the LCST. Whether nucleation and 
growth or SD occurs depends on how phase boundary is crossed. If the binodal line is 
crossed, the component becomes thermodynamically metastable. Under this scenario, 
phase separation is favorable but only achieved by nucleation and growth. If instead the 
spinodal line is crossed, SD will occur. The transition points between phase-separation 
and homogenous solution are therefore dependent on how temperature is changed. 
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Hysteresis of the reversible transition is related to the difference between spinodal and 
binodal curves. Note that phase separation is visually accompanied by an increase in 
turbidity or cloudiness of a solution. The cloud point is the temperature where the 
solution starts to become cloudy. And LCST is the cloud point at the critical composition. 
For simplicity, an experimentally determined cloud point is often reported rather than an 
LCST.  
While poly(N-isopropylacrylamide) (PNIPAAm) has dominated as the most well-
documented thermo-responsive polymer, there are growing interests on other types of 
polymers with LCST behaviors, such as poly(vinyl methyl ether) (PVME)[75], poly(2-
oxazoline)[76], and poly(N-vinyl-2-caprolactam) (PVCL)[77].  
PVCL is water soluble and biocompatible, with LCST in the vicinity of 
physiological temperature.[78] Its good biocompatibility is attributed to the fact that the 
amide group in PVCL is directly bonded to the hydrophobic backbone, thus its hydrolysis 
will not result in the production of cytotoxic small amide compounds.[79] The unique 
temperature dependent behavior of PVCL has been employed to prepare thermo-
responsive microgels for a variety of applications, including thermal sensitive drug 
delivery[80] and template for oxidative polymerization of pyrrole.[81, 82] It also has 
been used to stabilize proteases.[83] Furthermore, thermo-sensitive PVCL was recently 
employed by Zhuk and coworkers[84] for constructing pH responsive multilayers, which 
can be delaminated at high pH values.  
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1.4.2 Dual responsive polymers 
In conjunction with temperature, other stimuli including pH have been used in 
developing dual responsive polymers. For example, researchers have copolymerized 
NIPAAm with negatively charged carboxylic acid containing monomers such as alkyl 
acrylic acid,[85-88] N-acryloylavaline,[89] and succinic anhydride modified dextran[90]. 
Alternatively, monomers containing positively charged amino groups have also been 
commonly polymerized with NIPAAm, such as N,N-dimethylaminoethyl methacrylate 
(DMAEMA),[91] L-lysine,[92] and trans-4-hydroxyl-L-proline.[93] A few other 
polymers, which are not based on NIPAAm, have been reported with dual-responsive 
properties, such as  copolymers of di(ethylene glycol) methyl ether methacrylate 
(MEO2MA) with either methacrylic acid (MAA) or DMAEMA,[94] homopolymer of 
poly(N-ethylpyrrolidine methacrylate),[95] graft copolymers containing PMAA backbone 
and oligo(2-ethyl-2-oxazoline) (OEtOx) side chains,[96] and poly(amidoamine) 
dendronized poly(2-hydroxylethyl) methacrylate[97]. These dual responsive polymers 
have been explored in applications including control of micelle structures,[89, 91, 93] 
advanced drug delivery systems,[85, 88, 98] fabrication of dual functional nanofluidic 
devices,[86] and modification of gold nanoparticles.[90] 
Based on the LCST behaviors of PVCL polymers, I designed its functional 
derivative with pH-dependent LCST behaviors for smart drug delivery. The goal is to use 
the smart polymer as an alternative to enable tissue response specific release of anti-
inflammatory drugs. 
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1.5 Polymer chain conformation [73, 99]  
The freely jointed chain model is the simplest mathematical description of a 
polymer chain. In assumption, a single polymer chain has n bonds, each of length l, 
joined in a linear sequence with no restrictions on the angles between successive bonds. 
In this model, the mean-square end-to-end distance () is given by the following 
equation: 
  =   4  
However, it underestimates the real end-to-end distance of a polymer chain, 
omitting factors such as bond angle, conformation angle, excluded volume, steric 
hindrances, etc. The correction is represented by a constant, characteristic ratio C∞ by the 
following equation:
 
 
 R  = C"nl  5 
The end-to-end distance is difficult to measure. Instead, the radius of gyration, Rg, 
is often used since this quantity can be measured by a light scattering technique. The 
radius of gyration is the average distance from the center of the gravity to the chain 
segment. The mean-square value of the radius of gyration can be related to the mean-
square value of the end-to-end distance by the following equation: 
 R$ = % R  = &'()%   6 
In a crude approximation, each linear polymer chain occupies a space of a sphere 
with the dimension of Rg, At low concentrations, these spheres are separated from each 
other. As the concentration increases, they become congested and eventually touch each 
other. At the overlap concentration (c*), the whole volume of the solution is packed with 
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these spheres. The overlap concentration of the solution is given by the following 
equation:  
 c∗ = +,-./0123  7 
where M is the molecular weight of the polymer, and NA is the Avogadro’s 
number. 
When polymer concentration is below c*, the solution is considered dilute. The 
polymer chains are separated from each other and behave more or less independently. 
The chain interacts primarily with the solvent molecules. The solution is close to an ideal 
solution. The situation is different at concentrations above c*. The solution in this regime 
is considered semidilute. The polymer chains are overlapped and entangled. Their 
mobility is greatly reduced compared with the chains in dilute solutions. The 
thermodynamic properties of the semidilute solutions are greatly different from those of 
an ideal solution extrapolated to the same concentration. At an even higher concentration, 
the solution enters the concentrated regime in which each segment of the polymer chain 
does not have a sufficient space available.  
This dissertation studied the molecular behaviors in the LBL assembly by 
examining polymer chain dimension in aqueous solutions. The assembly process at the 
molecular level was proposed by correlating thickness of the layer with the polymer 
chain conformation information.  
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1.6 Dissertation Structure 
The objective of this dissertation research is to develop polymer mediated 
therapeutic interventions to help improve long-term performance of implantable neural 
electrodes. Failure of neural electrodes has been mainly attributed to glial scar formation 
and loss of neurons around the implant. To address each of the causes, I have tailor 
designed polymer based therapeutic interventions and studied their application toward 
neural electrodes. Furthermore, a pilot study was carried out to synthesize a dual-
responsive biocompatible polymer intended for smart drug delivery at the interface. The 
content of this dissertation is schematically shown in Figure 8: 
  
  
 
 
 
Figure 8
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. Overview of the dissertation research. 
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Chapter 2 
Synthesis and Characterization of Glucocorticoid Functionalized 
Poly(N-vinyl pyrrolidone): A Versatile Prodrug for Neural Interface 
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An article presenting part of the results in this chapter has been published on 
Biomacromolecules. [Cao Y, He W. Synthesis and Characterization of Glucocorticoid 
Functionalized Poly(N-vinyl pyrrolidone): A Versatile Prodrug for Neural Interface. 
Biomacromolecules 2010;11:1298-307.] The first author (Yu Cao) finished all of the 
experiments in this study. The corresponding author (Dr. Wei He) is advisor of Yu Cao 
and financially supported this work. 
2.1 Introduction 
Chronically implanted recording electrode arrays have the potential to improve 
the quality of life of patients suffering from partial or full paralysis. However, they often 
fail to function reliably in clinically relevant chronic settings. A potential solution to 
pharmacologically manage the tissue response to implanted electrodes is to enable self-
regulated drug release based on the severity of tissue response, without interfering with 
the electrical properties of the electrode. Integrating the surface modification method 
based on LBL assembly and stimuli-responsive drug conjugates, one could accomplish 
the proposed ‘smart’ and effective drug delivery at the neural interface (Figure 9). 
The multilayered-films constructed through hydrogen bonding mediated LBL 
assembly could undergo dissociation upon pH change, which could serve in the 
application of smart coatings and be particularly attractive to biosensors such as neural 
electrodes, where preserving electrical properties significantly limits the characteristics of 
any coating deposited on the surface.[45] 
Specifically, the electrode surface could serve as a temporary support for the 
drug-containing LBL multilayered film. Upon insertion into the tissue, the layers will 
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Figure 9. Surface modification of neural electrode with LBL assembly and drug release 
responsive to tissue reaction. 
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 quickly disintegrate under physiological pH, revealing the original electrode surface and 
eliminating the concern of coating-induced loss of electrode function (Figure 9). 
To directly link drug release with the extent of tissue response, the molecular 
characteristics of tissue response can be used as the trigger. Tissue acidosis, a decrease of 
extracellular pH of the tissue, has been observed after brain injury by many 
researchers.[100-103] Such a decrease in pH is also related to frustrated phagocytosis, a 
process that involves macrophages actively attacking non-phargocytosable surfaces, 
leading to the accumulation of degradative substances such as acid at the cell-biomaterial 
interface.[62, 104] Therefore, a drug conjugate with a pH sensitive moiety will 
potentially enable tissue response regulated drug release. Prodrug is useful to improve 
therapeutic properties of peptides, proteins, small molecules or oligonucleotides. In order 
to realize tissue acidosis controlled drug release, one could easily engineer a pH-sensitive 
trigger into the molecular structure of the prodrug. Hydrazone is one of the common acid 
labile linkages used in prodrug applications.[105, 106] It is relatively stable at 
physiological pH (7.4), but hydrolyzes at acidic pH normally found at pathological sites 
(below 6.0) such as tumors,[107, 108] infarcts,[109] and inflamed tissue.[110] Therefore, 
hydrazone bonding was used in this study to form prodrug of anti-inflammatory 
glucocorticoids. 
The other desired feature of the prodrug is its ability to participate in the LBL 
process based on hydrogen bonding. Thus a functional derivative of the hydrogen bond 
acceptor PNVP was used for drug conjugation. Several methods have been explored to 
introduce functional groups such as carboxylic acid and amine onto either the pendant 
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chain or polymer end.[111-115] The pendant carboxyl groups of PNVP derivative can be 
used for drug conjugation while the repeating lactam ring provides hydrogen bond 
accepting function in the LBL process. PNVP is a hydrophilic synthetic polymer 
generally known for its biocompatibility and non-antigenicity, and is considered safe for 
biological experiments.[67] Soluble PNVP is one of the most versatile and widely used 
pharmaceutical auxiliaries and topical disinfectants.[68] However, lack of common 
functional groups in PNVP limits its further applications such as conjugation with other 
biological therapeutics.  
In this chapter, I have synthesized a glucocorticoid functionalized PNVP prodrug 
that displayed responsive drug release in vitro under conditions mimicking inflammation. 
The feasibility of transporting the prodrug to the neural interface using the LBL method 
without permanently encapsulating the electrode was evaluated. The bioactivity of the 
prodrug and its released products was also examined in terms of anti-inflammatory 
potency and neurotoxicity. This newly developed drug delivery system could potentially 
resolve the dilemma between increasing drug loading capacity and maintaining the 
conductivity of electrode. Furthermore, it enables direct regulation of drug release by the 
tissue response, thus allowing more effective and active therapeutic treatment at the 
neural interface. 
2.2 Experimental Section 
2.2.1 Materials  
Diisopropylamine, azobisisobutyronitrile (AIBN), di-tert-butyl dicarbonate, N-
ethyl-N’-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), prednisolone, and 
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polyethyleneimine (PEI) with Mn = 1,800 g/mol were obtained from Sigma-Aldrich. 
Tetrahydrofuran (THF), N-vinyl-2-pyrrolidone (NVP), N,N’-dimethylformamide (DMF), 
n-butyllithium, tert-butyl carbazate (TBC) and trifluoroacetic acid (TFA) were obtained 
from Acros. Deuterated dimethyl sulfoxide, chloroform, and water were obtained from 
Cambridge Isotope Laboratories, Inc. Polyacrylic acid (PAA) with Mw = 450,000 g/mol 
was purchased from Polysciences, Inc. Hexanes, ethyl acetate, dichloromethane (DCM) 
and quartz slides were purchased from Fisher Scientific. Dialysis membrane (MWCO = 
500 Da) was obtained from Spectrum Lab, Inc. All reagents were used as received unless 
otherwise noted. 
2.2.2 Characterization  
1H NMR (300 MHz) spectra were recorded on a Varian Mercury 300 NMR 
spectrometer. Gel permeation chromatography (GPC) was performed at room 
temperature using PL-GPC 50 plus (an integrated GPC/SEC system from Polymer 
Laboratories, Inc.) with a refractive index detector. DMF was used as the carrier solvent 
at a flow rate of 1.0 mL/min. Standard monodisperse polystyrenes (Polymer 
Laboratories) were used for calibration. UV-vis spectra were measured using a UV-vis 
spectrometer (Biomate 5 from Thermospectronic). Ellipsometric measurements were 
performed on dry films in air using an L0116S Stokes ellipsometer (Gaertner scientific 
corporation) with He/Ne laser (632 nm) illumination at a 70° angle of incidence. A 
refractive index of 1.465 for the dry film was assumed. 
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2.2.3 Prodrug synthesis 
Synthesis of carboxylated NVP copolymer (COOH-PNVP). Monomer of 3-(tert-
butoxycarbonyl)-N-vinyl-2-pyrrolidone (TBNVP) was synthesized as described 
previously.[114] NVP (5.328 g, 1.6 mol/L), TBNVP (2.532 g, 0.4 mol/L), AIBN (0.148 
g, 0.03 mol/L) and freshly distilled THF (30 mL) were added into a 250 mL flask, and 
subjected to three freeze-thaw cycles to remove oxygen. Polymerization reaction took 
place at 65 °C for 22 h. The polymer was then precipitated in hexane, redissolved in THF 
and reprecipitated in hexane for purification. The obtained polymer (PTBNcoN) was 
dried in a vacuum oven at 55 °C overnight (6.555 g, 83% yield, Mw: 16,900 g/mol). The 
carboxyl groups (-COOH) were recovered by removing the t-BOC protecting groups 
using TFA. Briefly, PTBNcoN (6.259 g, 9.55 mmol t-BOC) was dissolved in DCM (15 
mL) followed by the addition of 15 mL TFA. After reacting for 4 h, the polymer was 
recovered by solvent evaporation and dialysis against deionized water overnight and 
lyophilization. The yield was 5.05 g (80%). 
Synthesis of NVP-hydrazide copolymer (PNVP-NH-NH2). COOH-PNVP (3.568 g, 
5.9 mmol COOH) and TBC (0.808 g, 5.9 mmol) was dissolved in 25 mL of ultrapure 
water. Aqueous solution of EDC (1.17 g, 5.9 mmol) was then added dropwise. The 
reaction mixture was stirred for 24 h at room temperature. Unreacted TBC and EDC were 
removed by dialysis against deionized water extensively. The product, t-BOC protected 
NVP-hydrazide copolymer (PNVP-NH-NH-BOC) was obtained by lyophilization (3.584 
g, 76%). To remove the BOC protecting groups, TFA was used. Briefly, PNVP-NH-NH-
BOC (1.171 g) was dissolved in DCM (10 mL) and TFA was added (10 mL). After 4 h of 
 30 
 
reaction at room temperature, the solvent was evaporated, and the purified PNVP-
hydrazide copolymer (PNVP-NH-NH2) was obtained by dialysis against deionized water 
extensively and lyophilization. The yield was 1.058 g (89%). 
Synthesis of NVP-glucocorticoid prodrug (PNVP-Pred). PNVP-NH-NH2 (0.712 
g) was mixed with the glucocorticoid drug prednisolone (1.204 g) in DMF and 50 µL of 
acetic acid was added as a catalyst for the reaction. The solution was kept stirring for 24 
h. The mixture was precipitated in water to remove unreacted prednisolone (limited water 
solubility 142 mg/L[116]) while the prodrug remained in the aqueous solution. The 
obtained solution was dialyzed against deionized water extensively and lyophilized to 
obtain prodrug (0.410 g, 38%). 
2.2.4 pH sensitive drug release  
Prodrug (10 mg/mL) was dissolved in either an acetate buffer (0.15 M, pH 5.0), or 
a phosphate buffer (0.15 M, pH 7.4). One millimeter of prodrug solution was then loaded 
to a dialysis tube (MWCO 500 Da) and incubated in 20 mL of corresponding buffer at 37 
°C. At selected time intervals, the solution outside the dialysis membrane (60 µL) was 
withdrawn for high-performance liquid chromatography (HPLC) analysis. A Thermo 
Scientific Finnigan HPLC system coupled with dual wavelength detector was used for the 
drug release study. A reverse phase C18 (Waters Sysmmetry, 4.6 × 150 mm, 5 µm) was 
used for the analysis with acetonitrile/water as the mobile phase. The flow rate was set 
constant at 1.0 mL/min. The UV detection wavelength was at 240 nm. The sample 
injection volume was 20 µL for all evaluations. A linear external prednisolone calibration 
curve was established. The amount of prednisolone released was quantified by converting 
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the UV absorbance at 240 nm against the standard calibration curve. All drug release data 
are presented as the amount of free prednisolone relative to the total prednisolone content 
in the prodrug conjugate. 
2.2.5 LBL assembly with PNVP prodrug (PNVP-Pred)  
The self-assembled films were prepared either on quartz slides or silicon 
substrates with a 100 nm thick oxide layer (University Wafer), depending on the specific 
characterization methods used. Before layer deposition, the silicon wafers were cut into 
small squares (1 x 1 cm). Both substrates were cleaned in a boiling piranha solution (3:1 
concentrated H2SO4 : 30% H2O2 v:v; piranha solution reacts violently with organics and 
should be handled with extreme caution) for 30 min, washed with copious amount of 
water and dried under nitrogen. The substrates were first immersed in a PEI solution (1.5 
mg/mL, pH = 7) for 30 min, followed by rinsing in water for 1 min. The PAA/prodrug 
multilayers were then assembled by alternating immersion of the substrates in solutions 
of PAA (0.5 mg/mL, pH = 3) and prodrug (0.5 mg/mL, pH = 3) for 5 min, respectively. 
Between each step, the excess polymer was removed by rinsing the substrates with HCl 
solution (pH = 3) for 1 min. All solutions were prepared using ultrapure water (Milli Q-
plus system, Millipore) with a resistivity of 18.2 MΩ·cm. The assembly process was 
monitored with UV-vis spectrometer and ellipsometry. The coated substrates were 
immersed in phosphate buffered saline (PBS, pH = 7.4) for 1 h, and subsequent 
ellipsometric measurements were carried out to characterize layer desorption. 
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2.2.6 Bioactivity of prodrug and its released products 
In vitro anti-inflammatory study of prodrug. A subclone of RAW264.7 murine 
macrophages (kindly provided by Dr. Tim Sparer of the University of Tennessee) were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS, Invitrogen), 1% L-glutamine and 1% penicillin/streptomycin. Cells 
were cultured at 37 °C, 5% CO2 and 95% relative humidity. For anti-inflammatory study, 
cells were seeded in 48-well tissue culture plates at a density of 1.0 × 105 cells/well and 
allowed to attach overnight. Culture medium was then aspirated and replaced with fresh 
medium. Cells were stimulated to generate nitric oxide (NO), a potent inflammatory 
mediator, with 100 ng/mL of lipopolysaccharide (LPS) (Sigma), and treated with solution 
of prednisolone, prodrug or precursor polymer (PNVP-NH-NH2) (concentration 
equivalent to 1.1 µM prednisolone) simultaneously. All treatments were done in 
triplicate. After 24 h of incubation, the amount of stable nitrite accumulated in the culture 
medium, the end product of NO production, was determined by Griess reagent 
(Promega).[116]  
In vitro anti-inflammatory study of products from prodrug release. Prodrug 
solution was prepared with either a PBS buffer (pH = 7.4) or an acetate buffer (pH = 5.0), 
and incubated at 37 °C. At various time points (day 1 and day 10), an aliquot of solution 
was withdrawn and stored at -20 °C. Prodrug solutions were also collected before 
incubation and noted as day 0 samples. Macrophages were cultured and activated as 
described in the previous section, and treated using the incubated prodrug solutions 
 33 
 
collected at day 0, 1, and 10, respectively. NO production was analyzed using the Griess 
assay.  
The results for Griess assay study were expressed as percentage to the untreated 
LPS stimulated control, and analyzed by analysis of variance (ANOVA) using a SAS 
software. Least squares means were compared by Least Significant Difference (LSD) 
test. For all analyses, significance was assigned for p < 0.05. All cell culture studies were 
repeated to account for biological variance.  
Primary cortical neuron culture. Cortical neurons were obtained from 9-day-old 
chicken embryos. Forebrains of the embryo were dissected, minced into small pieces, and 
enzymatically dissociated with 0.25% trypsin in PBS for 20 min at 37 °C, followed by 
inactivation with medium containing 10% FBS (Invitrogen). A cell pellet was obtained 
after a brief centrifugation, and mechanical trituration using a fire-polished Pasteur pipet 
was applied to further dissociate the cells. Cells were then preplated on a collagen-coated 
Petri dish and incubated for 1 h at 37 °C in a 5% CO2 atmosphere. This process has been 
reported to provide culture with 97% of neuron composition.[117] Purified neuronal cells 
were collected and resuspended for cell culture. 
In vitro cytotoxicity study. The cytotoxicity of the prodrug and its polymer 
precursor PNVP-NH-NH2 towards neurons was determined. Cortical neurons were 
seeded into wells of 24-well tissue culture plates precoated with Laminin at a density of 
5.0 × 104 cells/cm2 and cultured in DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin, and 1% L-glutamine at 37 °C in a 5% CO2 atmosphere for 2 
days. Cell culture medium was then aspirated and replaced with fresh medium 
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supplemented with either prodrug or PNVP-NH-NH2 (100 µM, equivalent to 
prednisolone). Cells were incubated for another 2 days and cell viability was determined 
using a WST-1 assay (Roche) according to the manufacturer’s instruction. Cell viability 
was calculated by normalizing the absorbance to that of the controls. Furthermore, a 
qualitative morphological study was performed simultaneously. Briefly, at the end of 
culture, cells were live stained with 0.05 v/v Calcein AM (Invitrogen) solution in PBS 
and incubated at 37 °C in a 5% CO2 atmosphere for 30 min. Samples were rinsed twice 
with PBS before and after fluorescence staining. Fluorescent images were collected using 
a 10× objective lens on a confocal microscope (Leica SP2, Germany).  
2.2.7 Prodrug diffusion  
Synthesis of fluorescent prodrug analog (FPNVP). The reaction is modified from 
a previous report.[118] PNVP-NH-NH2 (0.03 g) was dissolved in sodium carbonate 
buffer (16 mL) at pH 9. Fluorescein isothiocyanate (FITC) in anhydrous DMSO (0.15 
mL, 1 mg/mL) was added to the above PNVP-NH-NH2 solution. The solution was kept 
stirring for 10 h. The mixture was quenched by the addition of ammonium chloride (16 
mg) to a final concentration of 50 mM. The obtained solution was dialyzed against 
deionized water extensively in dark and lyophilized to obtain FPNVP (0.012 g, 40%). 
Diffusion experiment. The Si substrates were firstly coated with 8 bilayers of 
FPNVP and PAA using the LBL method mentioned in section 2.2.5. A 0.6 wt% SeaKem 
agarose solution was poured onto a Si wafer with 8 bilayers of (FPNVP-PAA). Gel was 
formed within 5 minutes. Then 1 mL PBS was added on top of the gel. The system was 
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kept in dark overnight at 37 °C. Then fluorescent images were captured. The software of 
Image J was used to analyze the fluorescent pictures to obtain quantitative data. 
2.3 Results and Discussion 
2.3.1 Prodrug synthesis and characterization  
In this work, the synthesized prodrug was based on PNVP and anti-inflammatory 
glucocorticoid drug of prednisolone. The prodrug was prepared following procedures 
outlined in Figure 10. The conjugation scheme can be easily translated to other members 
of the glucocorticoid family, such as dexamethasone and methylprednisolone. Due to the 
lack of reactive groups for drug conjugation in monomer (NVP), it is common to 
copolymerize NVP with other functional vinyl monomers. However, reactivity of NVP 
differs greatly from those of other monomers, which results in compositional shift from 
feeding ratio. Therefore, a derivative of NVP was used to copolymerize with NVP in 
preparing functional PNVP. The derivative, TBNVP, bears a protected carboxyl group at 
the α-position of NVP, and is expected to show similar radical reactivity with NVP due to 
the structure similarity between the two monomers. As shown in a, integration of 3CH2 
and 7CH3 revealed that the molar ratio of TBNVP in the prepared copolymer was 18 
mol%, suggesting good agreement with the monomer feeding ratio of 20 mol%. Thus, 
copolymerization of TBNVP and NVP monomers allows controlled introduction of 
functional groups into the polymer with little compositional drift. 
In order to render the prodrug susceptible to tissue acidosis, an acid labile 
hydrazone group was used to conjugate prednisolone to the functional PNVP.  
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Figure 10. Glucocorticoid prodrug synthesis via conjugation of prednisolone onto 
functionalized poly(N-vinyl pyrrolidone). 
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Briefly, the carboxyl group at the α-position of PNVP was exposed by acid removal of 
the t-BOC protecting group, and subsequently converted into hydrazide groups by 
reacting with tert-butyl carbazate followed by acid deprotection. The use of TFA for 
deprotection of t-BOC groups is highly efficient as reported in the literature[119] and 
further confirmed in this study by the disappearance of the characteristic t-butyl peak at 
δ1.33 in the NMR spectra (Figure 11b and d). Conversion of the functional groups can be 
obtained using integrations of 3CH2 and 7CH3. Briefly, PTBNcoN was fully converted to 
COOH-PNVP. Subsequently, 88.9% of the -COOH groups were converted to BOC-
hydrazide, followed by 100% conversion to unprotected hydrazide. This means that the 
composition of the copolymer prior to drug conjugation was 82 mol% of NVP, 16 mol% 
of NVP-NH-NH2, and 2 mol% of NVP-COOH. Prednisolone was conjugated onto the 
copolymer through formation of a hydrazone bond between the pendant hydrazide group 
of the copolymer and the ketone carbonyl group on prednisolone. Because prednisolone 
has poor solubility in D2O, d8-DMSO was chosen as the NMR solvent for comparison 
between free drug and prodrug, even though the prodrug has good water solubility. As 
shown from Figure 12, the 1H-NMR spectrum of prodrug presents signals between δ4.0 
and δ7.6, attributed to protons of the prednisolone moieties. It indicates success of drug 
conjugation to the copolymer. The degree of prednisolone conjugation to the polymer 
was determined by UV absorbance spectroscopy analysis of the prodrug solution. Figure 
13 showed UV spectra of 0.1 mg/mL solutions of prednisolone, prodrug, and its polymer 
precursor PNVP-NH-NH2.  
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Figure 11. 1H-NMR spectra of (a) PTBNcoN, (b) COOH-PNVP, (c) PNVP-NH-NH-
BOC and (d) PNVP-NH-NH2 in D2O. 
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Figure 12. 1H-NMR spectra of (a) prodrug PNVP-pred and (b) free drug prednisolone in 
d8-DMSO. 
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Figure 13. UV spectra of 0.1 mg/mL aqueous solution of (a) prodrug PNVP-pred, (b) free 
drug prednisolone, and (c) precursor polymer PNVP-NH-NH2. 
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The prodrug and prednisolone share the characteristic peak at 247 nm. Prednisolone 
solutions of various concentrations were prepared and the absorbance at 247 nm was 
measured to generate a calibration curve for prednisolone content calculation. The 
amount of prednisolone conjugated to the polymer was 160 mg/g prodrug, determined by 
comparison of UV absorbance spectrum of prodrug against the prednisolone calibration 
curve generated in our lab.[120, 121] Composition of NVP-pred in the prodrug was 
calculated as 6 mol%, indicating that 60% of the hydrazide groups were consumed for the 
conjugation. The polydispersity of the prodrug was 3.84 as characterized by GPC. 
Although only one degree of conjugation was studied in the present work as a proof-of-
concept, the level of functionalization and drug loading capacity can be easily tuned by 
varying the initial copolymer composition between NVP and TBNVP.  To characterize 
the release profile of the synthesized prodrug bearing acid-labile functional groups, two 
release conditions were used. One condition is a pH 7.4 buffer representing normal tissue 
and the other condition is a pH 5.0 buffer simulating severely inflamed tissue.[122] As 
expected, the hydrazone-containing prodrug demonstrated pH-sensitive drug release 
behavior. Within 25 days, the percentage of prednisolone released from the prodrug was 
always higher at acidic pH than at physiological pH (Figure 14).  
The faster drug release rate under acidic condition is characteristic of the 
hydrazone bond, as its hydrolysis rate has been shown to be accelerated in the presence of 
an acid.[106, 123] This result suggests that more anti-inflammatory drugs will be released 
in case of tissue acidosis, therefore potentially enabling more effective and active 
pharmacological management of inflammatory tissue response at the implant interface.  
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Figure 14. In vitro cumulative release of prednisolone from prodrug at different pH levels 
up to 25 days. Standard deviation is less than 5% of the mean value (n=3). 
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There are two carbonyl groups at positions 3 and 20 in the prednisolone structure, 
as shown in Figure 10. A question related to the reaction mechanism is that which group 
reacts with PNVP-NH-NH2 to form the prodrug. Inferred from the fact that no 
crosslinking occurred during the reaction, it is possible that these two carbonyl groups 
differ in reactivity. Because the carbonyl group attached to the six-membered ring 
(position 3) is stabilized by the conjugated structure, I suggest that the other carbonyl 
group is more reactive. Therefore, the carbonyl group attached to the five-membered ring 
(position 20) is thought to be the reacting group in the prodrug synthesis step. 
In order to directly identify which carbonyl group reacts with PNVP-NH-NH2, 
control experiments could be designed. This study can also shed light on the crosslinking 
concern caused by potential role of prednisolone as a crosslinker due to the presence of 
two carbonyl groups. Control reactions designed using commercially available chemicals 
are shown in Figure 15.  
The reaction and workup procedures will be the same with that described in 
section 2.2.3. NMR spectra will be collected to determine chemical structure of product 
from reaction 1 and 2. Specifically, residual peaks from R1 or R2 will be screened to 
prove if any reaction happened. There are four possible outcomes as show in Figure 15. 
Out of these four outcomes, if b or c happens, it will be a clear indication of 
which carbonyl group on prednisolone reacted with PNVP-NH-NH2. Result d is unlikely 
because either reaction 1 or 2 should occur based on the results of the reaction between 
PNVP-NH-NH2 and prednisolone.  
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 Possible outcomes from the control reactions: 
 Reaction 1 occurred Reaction 1 not occurred 
Reaction 2 occurred a b 
Reaction 2 not occurred c d 
Figure 15. Control reaction for illuminating the reactivity of the two carbonyl groups at 
positions 3 and 20 in prednisolone. 
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 If outcome a is observed, this will mean either carbonyl can react. Further control 
reaction could be carried out by mixing an equal molar amount of R1 and R2. The amount 
of R1 (or R2) will be kept in excess as compared to the amine group on PNVP-NH-NH2, 
such as at a ratio of 3:1. Then the structure of final product could be determined. From 
here, the reactivity of the two carbonyl groups can be finally confirmed. 
2.3.2 Application of prodrug for LBL assembly  
The approach of integrating prodrug within self-assembled multilayers has been 
previously reported. Thierry and co-workers used a hyaluronan ester prodrug of 
paclitaxel, a potent hydrophobic chemotherapeutic agent, as a polyanion to prepare 
polyelectrolyte multilayers with a natural polyamine chitosan.[124] In their study, drug 
release resulted from the hydrolysis of the ester bond and subsequent diffusion of 
paclitaxel out of the film, while the multilayers remained stable throughout the release 
study. In the present work, a less stable multilayered film was preferred considering the 
application towards neural sensors such as electrodes. Therefore, the PNVP hydrazone 
prodrug of prednisolone was used for LBL assembly based on hydrogen bonding. PAA 
and PNVP could be deposited on a variety of substrates using the LBL technique through 
the hydrogen bond between the carboxylic acid groups on PAA and carbonyl groups on 
PNVP.[40, 45, 125] The stability of hydrogen-bonded PAA/PNVP multilayers is limited 
to a particular pH range, and layer deconstruction usually occurs under physiological pH 
(7.4).[126] Such pH-dependent stability is in fact advantageous for neural electrodes. As 
mentioned earlier, there is a fine balance between effective coating-based localized 
release of therapeutics and the electrical functionality of the neural electrodes. With this 
 46 
 
destructible hydrogen bonding interaction, the neural electrodes can serve as a temporary 
support for film construction and transport the film to the tissue-electrode interface via 
implantation. The physiological pH will then quickly release the film off the electrode 
surface leading to an implanted bare electrode in the neural tissue surrounded by 
molecular components of the disintegrated film (Figure 9). Those components can exert 
therapeutic actions when needed if proper release triggers are engineered into the 
molecular structure. Since prednisolone was conjugated via the pendant functional groups 
of the PNVP, the prepared prodrug still contained the carbonyl groups, which can form 
hydrogen bond with PAA. Using the LBL technique, hydrogen-bonded PAA/prodrug 
multilayers were coated onto silicon substrates, a material commonly used in recording 
neural electrodes. Ellipsometric measurements (Figure 16a) revealed that film growth 
was a linear function of the number of PAA/prodrug bilayers deposited (for up to 8 
bilayers), with an average bilayer thickness of 27 nm. This trend was also confirmed by 
UV-vis spectrophotometry of the multilayered films on quartz substrates, as indicated in 
Figure 16b. The absorbance peak at 193 nm originates from PNVP of the prodrug layer. 
A linear increase of absorbance at 193 nm in relation to the number of bilayers was 
observed, suggesting film growth of PAA and prodrug.[127]  
To demonstrate that the PAA/prodrug multilayer film can be released from the 
silicon surface in a physiological environment, the coated substrates were immersed in 
PBS (pH = 7.4), and subsequent ellipsometric measurement confirmed the destruction of 
the multilayer coating within 1 h.  
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Figure 16. Assembly of LBL films. (a) Plot of ellipsometric film thickness versus the 
number of PAA/prodrug bilayers deposited on a silicon substrate. (b) UV-vis absorption 
spectra of multilayer films of PAA/prodrug after 2, 4, 6 and 8 bilayer depositions. Inset: 
Absorbance at 193 nm (contribution from PNVP) versus number of assembled bilayers. 
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The pH sensitivity of the hydrogen-bonded PAA/prodrug multilayer was 
consistent with other reports.[45, 126] This pH sensitive prodrug containing coating 
could be a simple yet effective approach to modify recording neural electrodes, in which 
one could incorporate a sufficient amount of prodrug to aid in managing the host 
response to the implanted electrode without the concern of sacrificing the electrical 
property of the neural electrode.  
Because of the versatility of the LBL technique, such a prodrug system can be 
easily applied to other implantable sensors where a permanent, drug embedded coating 
might compromise the sensing function of the device. It is worth mentioning that PEI was 
used as the base layer to prime the surface for subsequent LBL process. Although toxicity 
of PEI is a debatable concern for biological applications[128-130], only a minute amount 
of PEI was present on the substrate (i.e., it has been reported less than 0.1 g/cm2 of PEI 
deposited as a base layer for LBL[131]). Furthermore, toxicity of PEI depends on the 
molecular weight, where 2 kDa PEI was nontoxic even at concentrations as high as 45 
g/mL[132]. The PEI used in this study has a molecular weight of 1.8 kDa, and therefore, 
it is not expected to exert significant adverse effects on neurons.  
In this LBL assembly system of PAA/prodrug, PAA is chosen to facilitate 
deposition of prodrug in the dissociable coating. Actually, other polymers with 
carboxylic acid group could possibly substitute PAA. Therefore, polymers with good 
biocompatibility could be tried, which will be further discussed in chapter IV. 
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2.3.3 Bioactivity and biocompatibility of prodrug and its released products  
The prodrug was designed for suppression of host inflammatory response towards 
recording electrodes inserted in the CNS. Activation of microglia, the only resident 
phagocytotic cells in the CNS, was observed following injury caused by electrode 
implantation.[8, 133, 134] The activated microglia, also known as the brain macrophages, 
continually produce various cytotoxic and neurotoxic factors.[8] It has been suggested 
that inhibition of microglia activation is a potential strategy to reduce immune response 
against the electrode.[11, 30] In addition to microglia, electrode implantation inevitably 
damages the vasculature of the CNS, leading to extravasation of blood borne, monocyte-
derived macrophages into the CNS tissue. These macrophages act in concert with 
activated microglia to defend the CNS against the non-self electrode. Because of the 
functional similarity, the present study selected the readily available monocyte-derived 
macrophages instead of isolating primary microglia from neonatal rats to examine the 
anti-inflammatory effect of the prodrug and its released products. Specifically, the well-
established RAW264.7 murine macrophages were used. RAW264.7 murine macrophages 
are responsive to LPS stimulation and produce nitric oxide (NO) as a marker of 
activation. NO is a potent inflammation mediator molecule and also is responsible for 
oxidative stress induced cell death.[13] Studies have shown that if the activated 
macrophages were responsive to anti-inflammatory therapeutics, the amount of NO 
production will decrease.[116] Therefore, the extent of NO reduction could be taken as a 
measurement of anti-inflammatory potency of therapeutic materials. In the present study, 
the anti-inflammatory effect of prodrug and its released products were determined by 
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comparing the production of NO between the activated cells treated with these 
compounds and untreated control. It has been shown that glucocorticoids can exert anti-
inflammatory effects within a wide range of dosage, from 0.001 nM to 0.1 mM or 
higher[135]. In the present work, I selected a dosage in the middle of the range (i.e., 1.1 
µM of prednisolone) to assay NO production. 
The inhibitory effect of prodrug and its precursor polymer on NO production in 
RAW264.7 macrophages were compared (Figure 17). A 40% reduction in NO production 
was observed when the cells were treated with prodrug, suggesting that the prednisolone-
conjugated prodrug has an anti-inflammatory effect against activated macrophages. 
However, the anti-inflammatory effect of prodrug was less potent compared to activated 
cells treated with the same amount of free drug, which showed over 60% reduction in NO 
production.  
It is unclear at present how the prodrug exerts its anti-inflammatory action. From 
the release profile at pH 7.4 (Figure 14) I can rule out the possibility that a significant 
portion of the conjugated drug was cleaved off the polymer carrier and interacted with the 
activated cells after 24 h of incubation. Based on the mechanisms of the cellular actions 
of glucocorticoids reported by Buttgereut et al. [135], I speculate that all the free drug 
molecules can participate in both the genomic mechanisms and nongenomic mechanisms. 
However, in the form of prodrug, it is likely that the nongenomic, receptor-mediated 
mechanisms are dominant. Depending on the polymer chain conformations, it is possible 
that only a portion of the conjugated drug molecules will be accessible to the receptors. 
Therefore, the prodrug form is less effective to inhibit NO production than free drug.  
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Figure 17. NO production by LPS activated macrophages, LPS activated macrophage 
treated with either polymer PNVP-NH-NH2, prodrug PNVP-pred, or free drug 
prednisolone, respectively. Non-activated macrophages treated with polymer PNVP-NH-
NH2 alone were also included. Cells without LPS activation served as control. Data 
shown are average ± STD (n = 3). 
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It will be informative to elucidate the mechanism underlying the therapeutic effect of the 
prodrug in a future study. Along with the prodrug, I was also interested to examine 
whether the polymer precursor (PNVP-NH-NH2) had any biological activity, since it will 
be one of the major release products in addition to the conjugated drug. Of particular 
relevance are whether the polymer has any anti-inflammatory effect, and more 
importantly, whether the polymer is stimulatory towards macrophages.  
As shown in Figure 17, when LPS activated macrophages were treated with the 
polymer precursor (PNVP-NH-NH2) at a level equivalent to the prodrug, no significant 
difference was observed in the amount of NO produced as compared to LPS activation 
alone, suggesting that the polymer precursor had no anti-inflammatory effect. 
Furthermore, when non-activated macrophages were exposed to the polymer precursor, 
the level of NO production remained similar to that of the non-activated negative control. 
It implies that the polymer will not induce any macrophage activation and thus would be 
suitable as a drug carrier to treat host inflammatory response to implanted electrodes. 
The other important aspect of the bioactivity study was to determine whether the 
therapeutic nature of the drug was preserved after subjection to the conjugation reaction 
via the hydrazone linkage. To address this question, prodrug solution was prepared with 
either a PBS buffer (pH = 7.4, physiological condition) or an acetate buffer (pH = 5.0, 
inflamed tissue) and incubated at 37 °C. At various time points, an aliquot of solution 
was withdrawn and stored at -20 °C until the bioactivity study was performed. LPS 
activated RAW264.7 macrophages were used and treated with the various prodrug 
solutions mentioned above.   
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Figure 18. NO production by LPS activated macrophages with and without treatment of 
prodrug solutions subjected to release for up to 10 days at pH 5.0 and 7.4. Cells without 
LPS activation served as control. Data shown are average ± STD (n = 3). * indicates p < 
0.05. 
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The therapeutic effect was gauged through level of inhibition of NO production. As 
shown in Figure 18, when cells were treated with prodrug solutions obtained after 1-day 
incubation, the level of inhibition on NO production was similar to the original day 0 
samples, regardless of the buffer pH. However, when treating cells with samples 
collected after 10-day incubation, a significant improvement (p < 0.05) in NO inhibition 
was observed for the sample prepared in the acidic buffer, where the inhibition level 
increased from 40% to 50%; but the sample of physiological pH did not show any 
statistical change.  
On one hand, these results confirmed that more drug release occurred under acidic 
condition where hydrolysis of the hydrazone bond was accelerated, consistent with the 
HPLC data. On the other hand, these results indicated that the released prednisolone 
retained its therapeutic activity, suggesting that the conjugation scheme did not 
compromise the bioactivity of the drug. Though the HPLC data showed drug release at 
day 10 for the normal physiological pH, it is possible that the amount of free drug in the 
solution was below its therapeutic concentration, and therefore not able to further reduce 
NO production. Overall, these cell culture results proved that the synthesized prodrug 
was sensitive to pH and able to release more potent free drug at lower pH. It could be 
used as a smart drug delivery system to actively treat inflammation against implanted 
neural electrodes, that is, a more severe inflammatory response will result in further 
tissue acidosis which in turn triggers more drug release to counteract on the 
inflammation. 
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Besides its therapeutic effect, of equal importance to the neural electrode 
application is the biocompatibility of the prodrug in the CNS. It is critical that the 
prodrug and its released product, i.e. the polymer precursor PNVP-NH-NH2 do not 
exhibit toxicity towards neurons, which are the sole target of the electrode. Therefore, I 
studied toxicity both quantitatively and qualitatively. For quantitative analysis, the WST-
1 assay was adopted. It is a standard assay used widely for analysis of cytotoxicity. Its 
working principle is based on the reduction of a tetrazolium salt by cellular mitochondrial 
dehydrogenases to a water-soluble salt, which can be photometrically quantified at 450 
nm. In this assay, the untreated neurons were used as a positive control and all values 
from the experimental group were compared with this set of data. As shown in Figure 
19a, the reduction of WST-1 was unaffected by prodrug or its polymer precursor, and no 
significant difference was observed between the viability of treated neurons and the 
control. For qualitative analysis, neuron morphology was observed via a live Calcein AM 
staining. The confocal images (Figure 19b-d) illustrated that regardless of the treatment, 
the cortical neurons were viable (good fluorescent intensity) and displayed morphology 
and neurite extension comparable to the control. Both of the polymers used in the LBL 
process, that is, PNVP and PAA, are non-biodegradable. One will be concerned about the 
bioeliminability of these polymers in vivo. Although I used the well-studied high 
molecular weight PAA in this proof-of-concept study for LBL construction, future 
studies can use a degradable polymer such as poly(glutamic acid) to replace the non-
degradable PAA. For PNVP, even though it is non-degradable, it can be eliminated if the 
molecular weight is maintained below 100,000 g/mol.   
 Figure 19. (a) In vitro neural cytotoxicity of prodrug PNVP
PNVP-NH-NH2. Data shown are average ± STD (n = 3). Confocal images show 
morphology of neurons following 48 h treatment with either (b) prodrug PNVP
precursor polymer PNVP-NH
 
 
56 
 
 
 
-pred and precursor polymer 
-NH2, or (d) non-treated control. Scale bar = 100 µ
 
 
-pred, (c) 
m. 
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2.3.4 Prodrug diffusion in a simulated brain tissue model 
Distribution of prodrug in the brain tissue around the implanted electrode is an 
important parameter for clinical applications due to the importance of therapeutic 
concentrations to combat inflammation. Therefore, a simple diffusion experiment in a 
simulated brain tissue was designed to provide basic information of the therapeutic 
concentration. 
A silicon wafer was firstly coated with fluorescent prodrug analog. Then the 
coated silicon was embedded into an agarose hydrogel, simulating the gel-like brain 
tissue environment. After incubation of the system for a predetermined time, the 
fluorescent prodrug analog diffused away from the electrode (Figure 20). The fluorescent 
images were recorded using a fluorescent microscope. The concentration distribution of 
the prodrug analog around the electrode was therefore calculated.  
The raw images were shown in the appendix (Figure 50). The processed 
fluorescent intensity along the diffusion pathway was shown in Figure 21.  
The fluorescence intensity at 4200 µm was firstly subtracted as the background 
value to obtain corrected fluorescent intensity. To simplify the calculation, the intensity 
curve was divided into three regimes, with linear distribution in each regime (Figure 22).  
The equation for the simplified intensity, I(x), was shown below: 
  456) = 7 82,																																															6 < 250	−0.046 + 92,																250 < 6 < 1800
−0.000836 + 35,						1800 < 6 < 4200
C
 8 
where x is the diffusion distance from the surface of the Si wafer. 
  
 Figure 20. Scheme of prodrug diffusion in the simulated brain model
agarose gel. 
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Figure 21. Fluorescent intensity of prodrug analog as a function of distance away from 
the Si wafer. 
  
  
 
 
 
 
Figure 22. Approximation of 
distance away from the Si wafer
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The prodrug concentration at distance x, c(x), was obtained based on the 
assumption of its proportional correlation the fluorescent intensity, as shown in the 
following equation. 
  D56 = E456 9 
where σ is a constant.  
In the cube of the diffused prodrug analog (Figure 23), it is reasonable to assume 
the same concentration along the shank of electrode (z).  
Therefore, the total amount of prodrug in the gel block (n0) could be calculated 
according to the following equation:  
 F D56GH6 = 042000  10 
where A is the area of Si wafer. Furthermore, n0 can be expressed by the 
following equation: 
 0 = ΓJGK  11 
where Γ is the amount of polymer per layer from LBL assembly. A typical value 
is 1 mg/m2/layer, from many previous reports and my own QCM results. Therefore, 1 
mg/m2/layer is used for current calculation. 
N is the layer number for the prodrug analog. 8-layer was taken for calculation.  
Φ is the drug loading capacity of the prodrug. In the current study, Φ is taken as 
160 mg/g, which is the drug loading capacity of PNVP-pred.   
  
 Figure 23. Scheme of simplified cube of diffused prodrug 
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away from the Si wafer.
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Finally, the concentration of prodrug could be determined at any location along 
the substrate. Take the concentration at 100 µm away from the substrate for example, the 
concentration was calculated as 2.36 µM. The brief calculation procedures are shown 
below: 
E =  
F 456GH6-   
= ΓJGK
F 456GH6-   
 
=
1LM
L
NOPQ × 8	NOPQ	 ×
0.16	M
M × G	
G TF 82H6 + F 5−0.046 + 92H6 + F 5−0.0836 + 35H6-  U  
U  
V 
V 
 W
 
= 0.0000104	XM/L+ 
D5100	L = E45100	L = E × 82 
= 0.00085	XM/L+ 
= 2.36	Z	[QPHP\]^^P 
 The ultimate goal of this experiment is to determine the spatio and temporal 
distribution of therapeutic at any time period and any location. A more rigorous process 
will be a combination of theoretical prediction and experimental validation. Experimental 
results will provide parameters such as the diffusion constants for theoretical calculation 
and proofs for the theoretical models. Theoretical models will in turn give comprehensive 
understanding of the drug concentration distribution. The above model needs to be 
improved in several ways such as the reproducibility, accurate description of the 
fluorescent intensity curve, etc. Although the current model is very rudimental, it is a 
simple and first step toward determination of kinetics of drug distribution in the brain 
tissue.  
 64 
 
2.4 Conclusions 
A glucocorticoid-polymer prodrug was synthesized by conjugating prednisolone 
to functionalized PNVP through a hydrazone bond. Drug release from the prodrug was 
sensitive to pH as hydrolysis of the hydrazone linkage was enhanced under acidic pH. 
Besides being a drug carrier, the prodrug was also compatible with the LBL technique 
leading to hydrogen-bonded PAA/prodrug multilayers successfully deposited onto silicon 
wafers and quartz plates through LBL assembly. The prodrug and its released products 
demonstrated good biocompatibility with neurons, and the conjugated drug retained its 
therapeutic effect by successfully inhibiting NO production from activated macrophages. 
Collectively, these results suggest that the glucocorticoid-PNVP prodrug can serve as a 
promising and versatile drug delivery system. It can be easily applied to neural electrodes 
without compromising the electrical property of the implant, and can potentially realize 
tissue response-regulated drug release based on tissue acidosis. Future studies include in 
vitro anti-inflammatory study of prodrug on the brain macrophage microglia as well as 
astrocytes, application of the prodrug on implantable neural electrodes and investigation 
of the effectiveness of the prodrug in actively managing tissue response to electrodes in a 
rat model. 
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Chapter 3 
Water Soluble Antioxidant Derivative Poly(Triethylene Glycol Methyl 
Acrylate-co-α-Tocopheryl Acrylate) as a Potential Prodrug to Enable 
Localized Neuroprotection 
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An article presenting part of the results in this chapter has been submitted to Acta 
Biomaterialia. [Cao Y, He W. Water soluble antioxidant derivative poly(triethylene 
glycol methyl acrylate-co-α-tocopheryl acrylate) as a potential prodrug to enable 
localized neuroprotection.] The first author (Yu Cao) finished all of the experiments in 
this study. The corresponding author (Dr. Wei He) is the advisor of Yu Cao and 
financially supported this work. 
3.1 Introduction 
Reactive oxygen species (ROS) are a class of oxygen free radicals and related 
molecules that are capable of exerting oxidative stress on cells when produced in excess. 
When the amounts of ROS are generated beyond the limit of natural antioxidant defense 
systems like reductive glutathione (GSH) and antioxidant enzymes, cells start to lose 
normal functions followed by necrosis[136, 137]. ROS generation has been used to 
correlate inflammatory cell response to biomaterials in numerous in vitro 
biocompatibility studies. For example, nanoparticles were shown to trigger an oxidative 
stress on cells by inducing the production of intracellular ROS, leading to subsequent 
cellular toxicity cascade reactions [138, 139]. Another example of ROS implication in 
biomedical material application is the oxidative stress response resulted from degradation 
products of poly(lactic acid) (PLA) [140, 141]. Such a high relevance of oxidative stress 
is also demonstrated by recent renewed interest in regulating oxidative stress to modulate 
the tissue response to biomaterials and improve their biocompatibility.  
For biomaterials used in neural tissues, such as MEAs, it is of utmost importance 
to control oxidative stress. Very often, neuro-inflammation is accompanied by oxidative 
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stress [142, 143]. Furthermore, the insoluble nature of MEAs stimulates 
microglia/macrophage cells into a “frustrated” phagocytosis mode. The process of 
“frustrated” phagocytosis is known to produce excess degradative substances such as 
hydrogen peroxide in an effort to destroy the implant [144, 145]. The consequence of 
these molecular actions is cellular damage and death. Although there have been many 
studies using localized release of anti-inflammatory agents to control inflammation 
against MEAs, few reports have addressed direct protection of cells from oxidative stress.  
Astrocytes are one type of glial cells in the brain supportive of neuron functions. 
It has been shown that astrocytes can protect neurons from oxidant hydrogen peroxide 
toxicity [38, 39]. Therefore, we suggest that it is rational to shield astrocytes from 
oxidative stress associated with implantable MEAs. Such an approach could potentially 
lead to improving survival of neurons that are vital for long-term MEAs functions.   
To protect cells from oxidative stress, a common strategy is to use therapeutic 
antioxidants. There are a variety of natural antioxidant molecules serving physiological 
roles of scavenging ROS. These include α-tocopherol (vitamin E, Ve) , trans-ferulic acid 
[146], ascorbic acid [147], α-lipoic acid [148], as well as proteins such as glutathione 
peroxidase [149], and myo-inositol hexaphosphoric acid and its derivatives [150-152]. 
Among these molecules, the antioxidant potency of Ve lies in its capability to scavenge 
free radicals that cause lipid peroxidation and damage of cell membrane. Ve has been 
widely selected as a defense against oxidative damage in a biomaterial context. For 
example, Ve has been used as an additive to stabilize PU elastomer in vivo [153]. New 
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dialysis membranes coated with Ve have also been developed [154]. In this study, I 
choose Ve to serve as the antioxidant agent to protect astrocytes from oxidative stress.  
Successful localized delivery of Ve around MEAs for in vivo applications needs 
to overcome several hurdles. First, Ve is highly hydrophobic, which is unfavorable for its 
solublization and transportation in the predominantly aqueous environment presented by 
the physiological tissues [155, 156]. Second, use of Ve may be limited by factors such as 
unfavorable pharmacokinetics and a short action time due to fast metabolisation [157]. 
Last, the delivery strategy needs to be carefully designed to avoid any compromise of the 
electrical properties of MEAs. To address the first two concerns, one can adopt a prodrug 
approach, that is, converting antioxidants into polymeric antioxidants to improve the 
transport and metabolic stability of antioxidant molecules. Furthermore, the rate of drug 
degradation can be reduced, ensuring a longer presence than free antioxidants [158, 159]. 
Such prodrugs can be formed by linking antioxidant molecules to polymeric matrices 
through covalent bonds [160, 161]. For example, polymer-tocopherol prodrugs were 
synthesized to treat porcine sperm cell. The intracellular sperm levels of Ve were largely 
increased. As a result, the endogenous fatty acid degradation under oxidative stress was 
greatly reduced [161]. For the last concern of maintaining electrical properties of the 
implant, I will design the prodrug to be compatible with LBL assembly process to 
minimize any impedance burden to the MEAs.  
In this chapter, a synthetic antioxidant polymer derivative of Ve was designed 
with the goal to enable localized delivery of antioxidants to the neural tissue around the 
MEAs implant, and to present a pharmacological depot to protect cells from the injurious 
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oxidative stress. The applicability of using this antioxidant prodrug with MEAs was 
demonstrated through LBL film assembly on silicon substrates. In vitro astrocyte cultures 
were carried out to study the cytotoxicity and anti-oxidation potency of the prodrug. To 
elucidate the protective mechanism against oxidative stress, a free radical scavenging 
assay was also performed. 
3.2 Experimental Section  
3.2.1 Materials  
Acryloyl chloride, α-tocopherol, triethylamine, azobisisobutyronitrile (AIBN), 
polyethyleneimine (PEI, Mw = 2,000 g/mol), 2,2-diphenyl-1-picryl-hydrazyl (DPPH) and 
tannic acid (TA) were obtained from Sigma-Aldrich, USA. Deuterated chloroform was 
obtained from Cambridge Isotope Laboratories, Inc., USA. Poly(acrylic acid) (PAA, Mw 
= 450,000 g/mol) was purchased from Polysciences, Inc., USA. Tetrahydrofuran (THF), 
dichloromethane (DCM), hexane, ethyl acetate, and anisole were purchased from Fisher 
Scientific, USA. All reagents were used as received unless otherwise noted. Monomer of 
triethylene glycol methyl acrylate (TEGMA) was kindly provided by Dr. Bin Zhao in 
Department of Chemistry, UTK. 
3.2.2 General characterization  
1H NMR and 13C NMR spectra were recorded on a Varian Mercury 300 NMR 
spectrometer. Fourier transform infrared spectroscopy (FTIR) was carried out on a Bio-
RAD FTS6000 FTIR spectrometer. Gel permeation chromatography (GPC) was 
performed at room temperature using PL-GPC 50 plus (an integrated GPC/SEC system 
from Polymer Laboratories, Inc., USA) with a refractive index detector. THF was used as 
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the carrier solvent at a flow rate of 1.0 mL/min. Standard monodisperse polystyrenes 
(Polymer Laboratories, USA) were used for calibration. A Q-1000 differential scanning 
calorimeter (TA Instruments, USA) was used to characterize thermal behavior of the 
copolymers. UV-vis spectra were measured using a UV-vis spectrophotometer (Biomate 
5 from Thermospectronic, USA). Ellipsometric measurements were performed on dry 
LBL films in air using an L0116S Stokes ellipsometer (Gaertner scientific corporation, 
USA) with He/Ne laser (632 nm) illumination at a 70° angle of incidence. A refractive 
index of 1.465 was assumed for the dry film. 
3.2.3 Polymer synthesis  
The monomer α-tocopherol acrylate (VeAc) was synthesized (Figure 24a) based 
on prior literature [161]. Copolymerization of VeAc and TEGMA was conducted at 
different feeding ratios, with molar percentage of VeAc as 5%, 10%, 25%, and 50%. In a 
typical procedure, VeAc (0.362 g, 0.065 mol/L), TEGMA (3.107 g, 1.234 mol/L), AIBN 
(0.037 g, 0.019 mol/L), and anisole (12 mL) were added into a 50 mL flask. The mixture 
was then subjected to three freeze-thaw cycles to remove oxygen. Polymerization 
reaction took place at 70 °C for 5 h. The polymer was then precipitated in hexane, 
redissolved in anisole, and reprecipitated in hexane for purification. The obtained 
polymer (PVT) was dried overnight in a vacuum oven at 70 °C (3.029 g, 87% yield). 
3.2.4 LBL assembly    
The self-assembled films were prepared on silicon substrates with a 100 nm thick 
oxide layer (University Wafer, USA). Before layer deposition, the silicon wafers were cut 
into small squares (1 x 1 cm).   
 Figure 24. (a) Synthesis of monomer 
characterization of VeAc in CDCl
observation of peaks at chemical shifts of 6.62, 6.36 and 5.98 ppm, corresponding to the 
vinyl protons. (c) 13C NMR characterization of VeAc in CD
associated with the acrylate carbons are identified. 
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3. Successful acrylation of Ve is confirmed by the 
Cl3. Characteristic peaks 
 
 
1H NMR 
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All substrates were cleaned in a boiling piranha solution (3:1 concentrated H2SO4 : 30% 
H2O2 v:v; piranha solution reacts violently with organics and should be handled with 
extreme caution) for 30 min, washed with copious amount of water, and dried under 
nitrogen. The substrates were first immersed in a PEI solution (1.5 mg/mL) for 30 min, 
followed by rinsing in water for 1 min. The PAA/PVT (or TA/PVT) multilayers were 
then assembled by alternating immersion of the substrates in solutions of PAA (or TA) 
and PVT for 5 min, respectively.  
Between each step, the excess material was removed by rinsing the substrates 
with HCl solution (pH = 3.0) for 1 min. Solutions of PAA, TA, and PVT were prepared 
to a concentration of 0.5 mg/mL (pH = 3.0) using ultrapure water (Milli Q-plus system, 
Millipore, USA) with a resistivity of 18.2 MΩ·cm. The assembly process was monitored 
with ellipsometry. To evaluate stability of the multilayers under physiological conditions, 
silicon substrates coated with PAA/PVT or TA/PVT multilayers were immersed in 
phosphate buffered saline (PBS, pH = 7.4) for 10 min, and subsequent ellipsometric 
measurements were carried out to characterize the thickness of remaining films. 
3.2.5 Quartz crystal microgravimetry (QCM)  
QCM measurements were conducted at room temperature using a Q-sense device 
(E4) with a flow cell (Q-Sense AB, Västra Frölunda, Sweden). A gold-coated 5 MHz 
AT-cut crystal was excited at multiple overtones, and the change in the resonance 
frequency was recorded. After deposition of the initial layer of PEI (1.5 mg/mL), the 
chamber was washed with water, after which the solution of PAA or TA was introduced 
into the chamber and allowed to adsorb for 5 min. Subsequently, the chamber was 
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washed again with HCl (pH = 3.0) and then filled with PVT solution, allowing an 
adsorption time of 5 min. The multilayer film was then assembled by alternating 
incubations between PAA (or TA) and PVT. 
3.2.6 In vitro cytotoxicity assay  
In vitro cytotoxicity of the PVT prodrug was examined using the A172 human 
astrocyte cell line (ATCC, USA). Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Cells were maintained at 37 °C in 5% CO2 with 95% relative 
humidity. Prior to cytotoxicity test, cells were harvested using a trypsin–ethylenediamine 
tetraacetic acid (EDTA) solution (0.25% trypsin–0.038% EDTA) and diluted to a density 
of 5 × 105 cells/mL. The cell suspension was added into 96-well plates at 100 µL/well, 
and cells were allowed to attach overnight. Cell culture medium was then aspirated the 
next day and replaced with fresh medium supplemented with PVT at different 
concentrations (either 10 or 500 µM). Cells were incubated overnight and polymer 
cytotoxicity was determined using an MTT assay (Promega, CellTiter 96, USA) 
according to the manufacturer’s instruction. Positive (without any treatment) and blank 
(without cells) controls were also included. Cell viability was examined by comparing the 
absorbance of treated cells to that of the positive control. Statistical analysis was 
conducted using Student’s t-test. Cell morphology was also recorded using an inverted 
optical microscope (ZEISS Observer A1, USA). 
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3.2.7 In vitro cell protection against oxidative stress 
A172 astrocytes were harvested using trypsin–EDTA solution and diluted to a 
density of 3.3 × 104 cells/mL. The cell suspension was added into 96-well plates at 100 
µL/well, and cells were allowed to attach overnight. The cultures were then incubated 
with Ve or PVT at a concentration equivalent to 500 µM Ve for 1 h before exposure to 
hydrogen peroxide (500 µM) to induce toxic oxidative stress. After 16 h, cell viability 
and morphology were examined using the MTT assay and optical imaging, respectively. 
The protective effect was inferred from the percentage of cells survived by normalizing 
the absorbance of treated cells to that of control cells without hydrogen peroxide 
treatment. 
3.2.8 Free radical scavenging assay 
Ve was released from PVT by dissolving the prodrug in a saturated KOH solution 
with saponification at 70 °C for 30 min. Released Ve was extracted by hexane twice, 
followed by solvent evaporation. The amount of Ve recovered was quantified using an 
Agilent 1100 HPLC system with a variable wavelength UV detector. A reverse phase 
C18 column (Phenomenex, 4.6 × 100 mm, 2.5 µm) was used for the analysis with 
acetonitrile and methanol (95:5, v/v) as the mobile phase. The flow rate was set constant 
at 1.5 mL/min. A sample injection volume of 20 µL was used for all evaluations. 
Detection of Ve was made by UV absorption at 280 nm. The antioxidation property of 
the released Ve was examined using a DPPH free radical scavenging assay following 
procedures modified from a previous report.[162] Briefly, aqueous solution (1 mL) of 
various samples was added to 3 mL of freshly prepared DPPH solution (0.025 mg/mL in 
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methanol). The tested samples included PVT, released Ve from PVT, and commercial 
grade Ve, and the concentrations were kept the same to be equivalent to 350 µM Ve. 
Absorbance at 550 nm was measured on a UV-vis spectrophotometer. The percentage of 
remaining DPPH free radicals in each experimental sample was calculated by 
normalizing the corresponding absorbance to that of the control without any sample 
addition. 
3.2.9 Impedance measurement 
The effect of the multilayers of (PVT/PAA) on the electrical properties of Si 
MEAs was evaluated by impedance spectroscopy. A micromachined single shank acute 
probe (16 recording sites, model: A1×16-5mm-100-177-A16) obtained from NeuroNexus 
Technologies, Inc. was coated with (PVT/PAA) multilayers, and the impedance of the 
probe sites was measured before the coating, after 8 bilayers, and 16 bilayers, 
respectively. Electrochemical impedance spectroscopy was done using Precision 
impedance analyzer 4294A (Agilent). A solution of 0.1 M PBS buffer was used as the 
electrolyte. AC sinusoid signal of 5 mV amplitude, with the DC potential set to 0V was 
used as the input. The value of the impedance was determined around the biologically 
relevant frequency of 1 kHz. 
3.3 Results and Discussion 
Oxidative stress can impose a significant challenge on cell survival if not 
controlled properly. Such an issue is of particular relevance to delicate brain tissue as it is 
highly prone to oxidation damage. In order to ensure the proper function of devices 
implanted in brain such as recording MEAs, it is reasonable to suggest that a potential 
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strategy is to maintain a healthy state of brain tissue at the interface through localized 
delivery of antioxidants. Toward this goal, I proposed to use an antioxidant prodrug. The 
prodrug was designed to serve two key functions: carrier of antioxidants and readily 
applicable for MEAs through LBL assembly. These features were achieved through 
simple copolymerization of α-tocopheryl acrylate (VeAc) with triethylene glycol methyl 
acrylate (TEGMA) to make poly(triethylene glycol methyl acrylate-co-α-tocopheryl 
acrylate) (PVT) prodrugs. VeAc is a derivative of the potent natural antioxidant vitamin 
E (Ve). The phenolic hydroxyl group allows straightforward functionalization of Ve into 
a polymerizable VeAc monomer. TEGMA is selected as the co-monomer to both 
increase water solubility of the prodrug and endow LBL compatibility through its 
hydrogen bond accepting ethylene glycol units. 
3.3.1 Synthesis and characterization of the antioxidant prodrug 
The antioxidant prodrug PVT was prepared through a conventional free radical 
copolymerization of monomers TEGMA and VeAc (Figure 25) with AIBN as the 
initiator. Prior to polymerization, the synthesized monomer VeAc was verified through 
1H NMR and 13C NMR, and the results agreed well with the expected structure (Figure 
24b and c). A series of PVT prodrugs were prepared by varying the feed molar ratio of 
the two monomers. The number average molecular weights Mn of the copolymers were in 
the range of 14,000-25,000 g/mol with a relatively high polydispersity (), which is typical 
for acrylate polymers synthesized by free radical polymerizations in solution.  
  
  
 
 
 
 
 
Figure 25. Synthesis of anti
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-oxidant vitamin E based prodrug PVT.
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Table 1. Molecular weight and compositional data of PVT prodrugs. 
 
Prodrug VeAc (mol%) Mn (g/mol) PDI actual feeding 
PVT4 3.7 5 21,700 3.29 
PVT8 7.8 10 24,900 1.87 
PVT24 23.7 25 21,700 1.50 
PVT45 45.5 50 14,500 1.43 
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The chemical structure of the PVT prodrug was characterized with 1H NMR. As 
shown in Figure 26, a series of signals at chemical shift 3.35-3.75 ppm and around 4.20 
ppm corresponded to the alkoxy protons of the ethylene glycol units in the side chain of 
the TEGMA moiety. The peaks around 0.89 ppm originated from the methyl protons in 
the alkyl tail of the VeAc component.Based on the characteristic peak from TEGMA 
(4.20 ppm) and VeAc (0.89 ppm), chemical compositions of PVTs were calculated. The 
molar percentage of VeAc incorporated into the final copolymers was 3.7%, 7.8%, 
23.7%, and 45.5%, respectively.  
The use of copolymerization allows the preparation of a series of PVT prodrugs 
with different therapeutic capacities by controlling the copolymer composition. Since 
both monomers are in the acrylate family, similar reactivity is expected between the two 
monomers, and the actual composition of the obtained copolymer should be consistent 
with that in the initial feeding. Such an expectation is confirmed from the 1H NMR 
results, where the initial molar feeding ratio of VeAc ranging from 5% to 50% resulted in 
a final molar percentage of VeAc incorporated at 3.7% to 45.5%, respectively. Attempts 
have also been made to synthesize a homopolymer of VeAc. However, no polymerization 
occurred, which could be attributed to the antioxidant properties of the α-tocopheryl 
group. Although the exact cause is beyond the scope of this paper, a similar result has 
been reported showing low efficiency of making methacrylate copolymers with high 
molar percentage of Ve derived methacrylate [163]  
  
  
 
 
 
 
 
 
 
 
Figure 26. 1H NMR characterization of prodrugs (a) PVT4, (b) PVT8, (c) PVT24, and (d) 
PVT45 in deuterated chloroform. Characteristic peaks from each monomer were labeled.
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 The chemical compositions of PVTs were further confirmed using UV-vis 
spectroscopy. As shown in Figure 27, λmax of the Ve spectrum appeared at 292 nm, while 
that of PVT copolymers shifted to 285 nm. Such a blue shift in the peak absorbance can 
be attributed to the substitution of the phenolic –OH group in Ve with an ester group in 
the PVT polymer. No significant absorbance was observed between 260-320 nm for the 
polymer analog of the prodrug (i.e. PTEGMA). Using a predetermined standard curve of 
Ve absorbance, the molar composition of VeAc in PVT4 and PVT8 were calculated to be 
4.3% and 9.0%, respectively. These results were comparable to those obtained from the 
1H NMR spectra.  
Chemical structures of the monomer VeAc and PVT copolymer were also 
characterized by FTIR (Figure 28). The characteristic phenolic –OH group from Ve is 
absent in both VeAc and PVT since no peak was observed around 3509 cm-1, which 
corresponds to the –OH stretching. The strong absorbance around 1734 cm-1 in VeAc and 
around 1743 cm-1 in PVT corresponded to the stretch vibration of ester C = O group. 
Furthermore, absorbance peaks around 1637 cm-1 and 1580 cm-1 in VeAc were due to C 
= C stretching vibration from both the vinyl group and the phenyl group.  
Thermal behavior of the PVT copolymers was characterized using DSC (Figure 
29). All PVTs displayed a glass transition temperature (Tg) well below body temperature, 
ranging from -55 °C to -30 °C when the fraction of VeAc increased from 4 mol% to 45 
mol%.   
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Figure 27. UV spectra of (a) PTEGMA (10 mg/mL), (b) Ve (0.05 mg/mL), (c) PVT4 (1 
mg/mL), and (d) PVT8 (1 mg/mL) in ethanol solution.  
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Figure 28. FTIR characterization of (a) Ve, (b) monomer VeAc, and (c) prodrug PVT4.  
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Figure 29. DSC thermograms of prodrugs PVT4, PVT8, PVT24, and PVT45. Glass 
transition temperature, Tg, for each of the prodrug is -55, -52, -40, and -30 °C, 
respectively. 
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Such a correlation is expected as a higher amount of the bulky and rigid Ve pendant 
group will hinder the ability of the polymer chains to undergo segmental motion, thus a 
higher Tg. No melting peak was observed when the samples were heated to a temperature 
as high as 200 °C (Figure 30).  
Varying compositions of PVTs also provided us an opportunity to identify the 
highest antioxidant loading capacity while maintaining reasonable water solubility. As 
mentioned earlier, the highly hydrophobic characteristic of Ve hinders its transportation 
through the predominantly aqueous extracellular medium of the physiological tissues. In 
contrast to the nearly insoluble nature of Ve in water (0.021 mg/mL or 49 µM) [164], the 
PVT prodrugs can be formulated to achieve significantly higher  solubility. In particular, 
PVT4 is the most water soluble, at a feasible concentration of 3.1 mg/mL that 
corresponds to 500 µM of Ve. PVT8 and PVT24 possessed medium solubility (0.5 
mg/mL), while PVT45 exhibited the lowest water solubility (0.02 mg/mL). The trend of 
water solubility correlates well with our expectation that the more of the hydrophobic 
VeAc monomer is incorporated into the prodrug, the less water soluble it will become. 
Water solubility of the prodrug is also highly relevant for its practical deployment 
to the tissue-implant interface using the LBL method, since the most commonly used 
solvent for LBL is water. Typically, I have been using a minimum concentration of 0.5 
mg/mL for our LBL assembly processes [34]. Therefore, prodrug PVT45, which has the 
highest molar percentage of VeAc, is not applicable for use in LBL. 
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Figure 30. Full DSC thermograms of prodrugs PVT4 and PVT45. 
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3.3.2 Application of PVT for LBL assembly  
LBL is a simple and convenient technique for surface modification of biomedical 
implants. Hydrogen-bond mediated LBL has been proposed to obtain well-engineered 
multilayer structures on neural MEAs to resolve the traditional dilemma between drug 
loading and preservation of electrical property of electrodes [34]. In the current work, I 
took advantage of the tunable stability of hydrogen bonding and rationally designed LBL 
parameters to achieve the bonus feature of forming a drug depot around the implant. As 
proposed schematically in Figure 31, prodrug-embedded detachable multilayers can be 
prepared on the electrode by incorporating an underlying sacrificial multilayer that is 
dissociable at physiological pH. Such a design could help confine the polymer 
therapeutics within the vicinity of the implant-tissue interface and exert therapeutic 
actions locally.  
To realize the design, two types of hydrogen-donating molecules were needed to 
form hydrogen-bonding with our hydrogen-accepting prodrug PVT. Among the many 
well–studied hydrogen-donating molecules, I selected poly(acrylic acid) (PAA) that is 
rich in carboxyl groups, and tannic acid (TA) that is rich in phenolic hydroxyl groups [55, 
165] (Figure 32a and b). Intermolecular hydrogen bonds are available between the 
hydrogen-accepting ether oxygen in the pendant ethylene glycol groups in PVT and the 
hydrogen-donating carboxyl groups in PAA or phenolic hydroxyl groups in TA. PAA is 
chosen for physiologically disruptable layers because of its low pKa (4.3), while TA is 
employed to maintain layer stability due to its high pKa value (8.5). The additional 
benefit of using TA is to capitalize on its biological properties such as antibacterial and 
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antioxidant activities [166]. The PAA/PVT and TA/PVT multilayers were constructed on 
silicon wafers with PEI as a precursor layer. Silicon is selected as the substrate because of 
its prevalent use for implantable neural MEAs [47, 48].  
Ellipsometric measurements showed the layer thickness increased linearly with 
the layer number, allowing easy control of drug loading capacity (Figure 32c). Eight 
bilayers of PAA/PVT and TA/PVT were 277 nm and 114 nm thick, respectively. For the 
same number of layers, a thicker film was obtained using PAA/PVT compared to that 
with TA/PVT. Such a difference could be due to molecular size disparity, as PAA has a 
much higher molecular weight (450,000 g/mol) than TA (1701.2 g/mol). To demonstrate 
the tunable stability of multilayers prepared with the same PVT prodrug, a simple 
immersion test was done in PBS, simulating the physiological condition of human tissue. 
The stability was characterized by the change of film thickness before and after 
immersion for 10 min. As shown in Figure 32d, a drastic decrease in film thickness, from 
277 nm to 4 nm, was observed for PAA/PVT multilayers. The remaining 4 nm film can 
be attributed to the precursor PEI layer along with the adsorbed first PAA layer. It 
indicates a significant film loss (more than 98% in thickness), which is attributed to the 
low pKa of PAA (4.3). At physiological pH of 7.4, the carboxyl groups of PAA became 
deprotonated, resulting in disruption of hydrogen bonding between PAA and PVT, which 
in turn led to film dissociation. In contrast, the TA/PVT multilayers remained stable as no 
significant change was noted in the film thickness after exposure to PBS (d).  
  
  
 
 
 
 
 
 
 
 
 
 
Figure 31. Schematic illustration of proposed use of prodrugs for 
implantable neural MEAs with 
antioxidants. The antioxidant prodrug PVT can be incorporated in two designs, 
dissociable layers constructed with poly(acrylic acid) (PAA), and stable layers made with 
tannic acid (TA) to serve as drug depots.
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LBL assembly to enable localized delivery of 
 
 
 
  
 
 
 
 
 
 
Figure 32. Schemes of LBL multilayer assembly pa
Hydrogen bonds formed between prodrug PVT and (a) PAA or (b) TA drives multilayer 
growth. (c) Film growth was monitored by ellipsometric measurement of film thickness 
as a function of number of PAA/PVT or TA/PVT bilayers. (d)
containing multilayer films in physiological pH 7.4 phosphate buffer was examined by 
comparing the film thickness before and after incubation.
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The high pKa (8.5) of TA provided stability for the TA/PVT multilayers due to the lack 
of ionization of phenolic groups at physiological pH, therefore, preserving strong 
hydrogen bonding between TA and PVT. 
I also monitored film buildup as a function of the bilayer number in situ by 
following the frequency change (∆f) with a QCM. As a complementary method to the 
ellipsometry technique that characterized the dry multilayer films, QCM allowed studies 
of in situ film growth in a hydrated state. As shown in Figure 32 and Figure 33a, a 
comparison of the results showed that for eight bilayers of PAA/PVT, the ellipsometric 
thickness was 277 nm and the QCM thickness was 414 nm. For TA/PVT multilayers, the 
values were 114 and 342 nm, respectively, indicating an even higher degree of swelling 
for this layer configuration. Considering that the TA/PVT multilayers are designed to 
serve as the antioxidant reservoir situated at the periphery of the interface, its ability to be 
well hydrated is highly desirable to minimize any irritation of the surrounding soft brain 
tissue.  
Another advantage of the QCM technique is that it allows the determination of 
adsorbed mass by converting the frequency change using the Sauerbery equation [167]: 
 mQCM = C 
∆_
`   12 
The mass deposited on the crystal, mQCM, is proportional to the normalized 
frequency shifts, ∆fi/i, where i is the overtone number. For crystal sensors with a 
resonance frequency of 5 MHz, the mass sensitivity constant C is 17.5 ng Hz cm-2, and 
the frequency shift for the third overtone (i.e. i = 3) was used to determine mQCM.  
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Figure 33. In situ characterization of multilayer growth on gold crystals using QCM. (a) 
QCM frequency shifts and calculated film thickness during alternating deposition of PAA 
and PVT or TA and PVT, and after incubation in PBS to demonstrate film stability. (b), 
(c) Evolution of adsorbed Sauerbrey mass (Γ) plotted against layer numbers for PAA (or 
TA), PVT, and total mass deposited.   
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The mass information is essential for in vivo applications, as it forms the rationale 
for finding the number of layers for a therapeutic concentration of the prodrug following 
MEAs implantation. The calculated Sauerbrey mass for PAA/PVT and TA/PVT 
following each layer deposition is shown in Figure 33b and c. For both multilayer 
configurations, the mass increase per PVT layer appeared to be constant shown by the 
linear increase in the Sauerbrey mass; whereas for the complementary PAA or TA layer, 
the mass increase was close to exponential with an initial “slow-growing” regime. For 
eight bilayers of deposition, the total mass adsorbed for PAA/PVT and TA/PVT was 73 
and 60 µg/cm2, respectively. The mass contribution from PVT layer deposition was 
higher than that from either PAA or TA layer, accounting for ~60% of the total mass. 
Furthermore, the difference in multilayer stability in PBS was confirmed with QCM. A 
significant recovery in the resonance frequency was quickly observed for the PAA/PVT 
combination (within one minute of PBS incubation), indicating the rapid loss of 
deposited multilayers (Figure 33a), whereas no change was noted for the TA/PVT 
multilayer coated crystal.  
In order to shed some light on the molecular behavior of the LBL assembly, 
radius of gyration (Rg) and critical overlap concentration (c*) of polymers are calculated, 
according to equations 6-7 shown in section 1.5. Take PAA/PVT system for example, the 
results are tabulated in .  
Rg values of PAA and PVT are 21 nm and 3 nm respectively. c* values of PAA 
and PVT are 20 and 336 mg/mL respectively. The polymer concentration for LBL 
assembly is 0.5 mg/mL, much smaller than c*.   
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Table 2. Molecular parameters of PAA and PVT. 
 
 
C∞ l (nm) n M (g/mol) Rg (nm) 
c*  
(mg/ml) 
PAA 9a 0.154a 12500 450000 21.08732 19.04073 
PVT 11b 0.154c 200 21700 2.948875 335.7574 
 
a Data are cited from handbook[168];b Data are from a similar polymer, poly (ethyl 
acrylate) in handbook[168]; c The chain length is assumed to be that of acrylic acid. 
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Therefore, adsorption of polymer is from non-overlapping chains in solutions. 
According to the QCM results, the average layer thickness is 26 nm. Referred to a 
previous report,[46] the molecular behaviors of the layer adsorption are proposed in 
Figure 34. The individual polymer chain is adsorbed onto a surface due to the hydrogen-
bonding interaction. Polymer chains are then extended and reorganized to form tails and 
loops extending from the surface. 
It should be noted that in the above calculation process, several assumptions are 
made for simplicity. Even though many estimations and limitations exist in the 
calculation, it can provide a semi-quantitative insight on the molecular level of the LBL 
process.  
3.3.3 Cytotoxicity study of PVT 
Besides satisfying the requirement of LBL compatibility, successful use of the 
antioxidant PVT prodrug for MEAs implantation also calls for high biocompatibility. 
Therefore, cytotoxicity of the prodrug on astrocytes was examined both quantitatively 
and qualitatively. A commercially available A172 human astrocyte cell line was chosen 
for this purpose. Since the Ve residue is linked to the acrylic backbone through a labile 
ester bond, the prodrug could be hydrolyzed in the physiological environment and give 
off Ve and the corresponding acrylic polymer. For this reason, cytotoxicity of these 
potential released products, i.e. Ve and the polymer (approximated with a homopolymer 
PTEGMA), was also tested. Because PVT4 has the highest water solublility among the 
prepared PVT prodrugs, it was selected for all the in vitro biological studies.  
  
  
 
 
 
 
Figure 34. Proposed molecular behavior of polymer chains during LBL process mediated 
by hydrogen bonding. 
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Two concentrations equivalent to Ve were used for cell treatment, 10 µM and 500 µM. In 
order to ensure dissolution of Ve at high concentrations, dimethylsulfoxide (DMSO) was 
introduced as a co-solvent. The highest concentration used for cell culture was equivalent 
to 500 µM of Ve, a value consistent with subsequent antioxidation study.  
As shown in Figure 35, cells exposed to the PVT prodrug were as healthy as cells 
in the control culture regardless of the prodrug concentrations. In comparison, for both 
Ve and PTEGMA, cells showed good viability upon low dose treatment, while a 
slightdecrease in viability (i.e. ~ 80% of the control) was observed for the high dose 
condition. For the polymer PTEGMA, the slight toxicity could be attributed to residual 
organic solvents in the polymer. Such an effect was also reflected from the difference in 
cell morphology as shown by the qualitative phase contrast images (Figure 36). Unlike 
the polarized spread shape presented by cells in the control culture, a more rounded 
morphology was observed from cells exposed to the high concentration of PTEGMA. 
3.3.4 Antioxidation study of PVT 
Antioxidation property of PVT was investigated using A172 cells due to the 
protective roles of astrocytes to neurons [38, 39, 169]. Hydrogen peroxide was chosen as 
the oxidant stimulant because of its physiological relevance [170, 171]. Cell viability was 
used as a caliber to examine whether the PVT prodrug can protect cells from oxidative 
stress. Proper test conditions, including cell density, cytotoxic concentration of H2O2 and 
protective concentration of Ve toward A172 cells, as well as exposure time were first 
identified from pilot experiments.   
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Figure 35. In vitro cytotoxicity of Ve, antioxidant prodrug PVT, and precursor polymer 
analog PTEGMA on A172 astrocytes at concentrations of 10 and 500 µM (equivalent to 
Ve). Data shown are average ± STD (n = 3). * p < 0.05. Statistical significance is 
compared with the non-treated control. 
  
 Figure 36. Representative phase contrast photomicrographs of cultured
subjected to various treatments for cytotoxicity study. Non
shown for comparison. Scale bar = 100 µm
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A172 cells were challenged with hydrogen peroxide at at 500 µM that is sufficient 
to induce significant oxidative stress and cause cell death. As shown in Figure 37a, cells 
treated with hydrogen peroxide alone showed a very low survival rate, less than 10%. 
When antioxidant Ve was added to the culture, it effectively protected cells from toxic 
hydrogen peroxide, as the survival rate was improved to 68%. When cells were treated 
with PVT prodrug at a concentration equivalent to 500 µM Ve, a viability of 43% was 
obtained, which is indicative of protection. The protective effect is also supported by 
qualitative morphological observations. In contrast to the characteristic polarized shape 
with processes shown by healthy astrocytes (Figure 37c), marked morphological change 
was observed for cells experiencing severe oxidative stress, resembled by strong 
shrinkage of cell bodies and degeneration of processes (Figure 37d). With Ve or PVT 
treatment, an intermediate state was observed, where both polarized and degenerated 
cells were present (e and 7f). A higher percentage of polarized cells were seen in Ve 
treated culture (Figure 37e) than PVT treated cells (Figure 37f), suggesting a lower 
degree of cell protection by PVT. 
It is summarized from above results that treatment with antioxidant Ve at 500 µM 
showed substantial cytoprotection. While PVT with an equivalent Ve concentration was 
also able to reduce cell death from H2O2 induced oxidative stress, the extent of protection 
is lower than Ve supplemented to the culture in its free form. The protective mechanism 
of Ve has been largely attributed to its capacity to scavenge free radicals that cause lipid 
peroxidation and damage of cell membrane. Specifically, it can donate the phenolic 
hydrogen to free radicals. 
 Figure 37. (a) In vitro protection of A172 astrocytes against injurious oxidative stress 
induced by hydrogen peroxide (H
(b) Antioxidation activity determined by the DPPH free radical scavenging method.
(f) Representative phase contrast photomicrographs of cultured A172 astrocytes 
subjected to various treatments. Scale bar = 100 µm.
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2O2).  Data shown are average ± STD (n=3). * 
 
 
 
p < 0.05. 
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Considering the essential role of the phenolic group for antioxidation, I hypothesized that 
the cytoprotective effect shown by the PVT prodrug was a result of hydrolysis of the 
labile ester bond between Ve and polymer chain, leading to the release of Ve in its active 
form. 
 To test this hypothesis, antioxidant property was further studied using a free 
radical scavenging method to elucidate the protection mechanism of PVT. DPPH is a 
stable free radical useful for the investigation of antioxidation activity of compounds. 
DPPH radical shows a characteristic absorbance peak around 550 nm. When interacting 
with antioxidants such as Ve, DPPH radical can be reduced through abstraction of 
transfer labile phenolic hydrogen atoms and the corresponding absorbance at 550 nm 
decreases. The extent of radical scavenging, which correlates with antioxidant potency, 
can be measured by the amount of decrease in absorbance.  
As a positive control, fresh Ve was added to DPPH solution at a concentration of 
350 µM and 90% of radicals were consumed (Figure 37b). When the prodrug PVT was 
added at a concentration equivalent to 350 µM Ve, no free radical scavenging effect was 
observed with almost 100% radical remaining at the end of reaction. PVT was unable to 
interact with DPPH free radicals due to the lack of phenolic hydrogen. In contrast, when 
DPPH was treated with Ve released from the PVT prodrug by disruption of the ester 
bond, the effect was comparable to that with fresh Ve. This result suggests that the 
released Ve retained its antioxidant potency and that the PVT protection of cells from 
oxidative stress was derived from the breakage of the ester bond and release of Ve in an 
active form. Such a mechanism correlates well with those reported on antioxidation 
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activity of esterified derivatives of phenolic antioxidants [172]. The lower degree of 
cytoprotection by PVT can be a result of slower release of Ve from PVT. It is well known 
that hydrolysis of ester group is closely dependent on water accessibility around the 
chemical bond [173, 174]. The strong hydrophobicity and steric hindrance of the Ve 
segment can limit water diffusion and slow down degradation. 
3.3.5 Electrical property of the modified electrode 
Neural electrodes were coated with (PVT/PAA) layers using the LBL technique, 
and the electrode impedance was measured before and after coating. This experiment was 
designed to examine the influence of coatings on the conductivity of the electrode. The 
thickness of coatings is expected to be the important parameter. Thin layers will not 
change the impedance, while thick coatings could increase the impedance significantly. 
In the latter case, the coated electrode will be immersed into PBS and the dissociable 
property of (PVT/PAA) coatings will be proved from the impedance data of the recording 
sites. It is expected that after incubation of the coated electrode in PBS, the coatings will 
dissociate and the conductive recording sites will be exposed, returning the impedance to 
original values.  
The images of the electrode before and after coatings are shown in Figure 38. The 
electrode was wrapped with some fluffy films around the tip, which could possibly be the 
polymer complex. After 16 bilayers of deposition, the impedance is still low, comparable 
to the uncoated electrode (Figure 39). The results demonstrate that current coated layers 
did not change the electrical property of the electrode.  
  
  
 
 
 
 
 
 
 
 
 
Figure 38. Photomicrographs of a Michigan 
of 8 bilayers of (PVT/PAA)  
(a) 
(b) 
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Figure 39. Impedance of recording sites after 8-bilayers (LBL (8)) and 16-bilayers (LBL 
(16)) of LBL coatings. The value of the bare sites before coating was also shown for 
comparison. 
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3.4 Conclusion 
Compositionally controllable antioxidant polymeric therapeutics based on Ve 
were prepared. A significant improvement in the water solubility of Ve was observed. 
The synthetic PVT prodrug can be used to modify substrates of neural MEAs implants 
through hydrogen-bond mediated LBL technique. Multilayers with tunable stability at 
physiological condition could be achieved simply by engineering the layer composition. 
In vitro biocompatibility study showed that the PVT prodrug was non-cytotoxic toward 
A172 human astrocytes. Furthermore, the prodrug was able to reduce astrocyte death 
from hydrogen peroxide induced oxidative stress through the release of Ve in its active 
form. Future studies include evaluation of protection of cortical neurons from oxidative 
stress with the PVT prodrug and its effectiveness in improving the long-term function of 
implantable neural MEAs in vivo. I believe that the strategy of using antioxidant prodrug 
for direct cell protection from oxidative stress induced cell death provides a new 
opportunity to improve the pharmacological control of brain tissue response to MEAs. In 
addition to neural implant applications, our prodrug could also be applied to other 
medical implants where reducing oxidative stress is essential. 
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Chapter 4 
Functionalized Biocompatible Poly(N-vinyl-2-caprolactam) with pH-
dependent Lower Critical Solution Temperature (LCST) Behaviors 
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An article presenting part of the results in this chapter has been published on 
Macromolecular Chemistry and Physics. [Cao Y, He W. Functionalized biocompatible 
poly (N-vinyl-2carprolactam) with pH-dependent lower critical solution temperature 
(LCST) behaviors. Macromolecular Chemistry and Physics, 2011, 212.] The first author 
(Yu Cao) finished all of the experiments in this study. The corresponding author (Dr. Wei 
He) is advisor of Yu Cao and financially supported this work. 
4.1 Introduction 
PVCL is water soluble and biocompatible, with LCST in the vicinity of 
physiological temperature.[78] In conjunction with temperature, other stimuli including 
pH have been used in developing dual responsive polymers. These dual responsive 
polymers have been explored in applications including control of micelle structures,[89, 
91, 93] advanced drug delivery systems,[85, 88, 98] fabrication of dual functional 
nanofluidic devices,[86] and modification of gold nanoparticles.[90] 
In order to introduce dual responsiveness to temperature and pH into PVCL based 
materials, a similar copolymerization approach is commonly used, where VCL monomers 
are copolymerized with other vinyl monomers such as MAA or acrylic acid (AA). For 
example, aqueous solutions of linear copolymer of VCL and MAA with variable 
compositions were prepared and the copolymers exhibited compositionally dependent 
coil swelling behavior as a function of both pH and temperature.[175] However, similar 
to its counterpart in the N-vinylamide family, such as N-vinyl-2-pyrrolidone (NVP), VCL 
exhibits significantly lower reactivity comparing to methacrylates and acrylates due to 
the inherently low reactivity of N-vinylamide.[82] Such drastic disparity in reactivity 
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ratio makes compositional control a major concern in copolymerization-based 
functionalization of VCL polymers. In order to minimize compositional heterogeneity in 
the copolymers, special techniques such as gradual feeding strategy has been 
proposed.[176] Alternatively, one could consider copolymerization of structurally similar 
monomers of VCL that bear functional groups to obtain homogeneous copolymers. For 
example, Aoyagi and coworkers designed a reactive monomer, 2-
carboxyisopropylacrylamide (CIPAAm), a derivative from N-isopropylacrylamide 
(NIPAAm).[177] They showed that copolymerization of CIPAAm with NIPAAm 
resulted in homogeneous copolymer compositions and improved the phase transition 
sensitivity.  
In this chapter, the same principle was applied by copolymerizing VCL with its 
functional derivative 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam (TBVCL), and 
improved compositional control was achieved. The protected carboxyl groups in the 
TBVCL units were converted to free carboxylic acids in the copolymer. Besides 
maintaining the intrinsic thermo-sensitivity, the incorporated carboxyl groups enabled 
pH-modulated LCST behavior. Sharp and reversible response was observed across a 
broad range of pH values. The carboxyl groups can also provide an easy access for 
further conjugation of bioactive moieties such as drugs, peptides, and proteins. Using 
NIH/3T3 fibroblasts, I demonstrated that this PVCL copolymer was non-cytotoxic at low 
concentrations. This simple PVCL copolymer with multi-characteristics, including 
thermal and pH sensitivity, and reactivity for conjugation, will further expand the 
biomedical applications of PVCL and provide a new option to the growing list of dual-
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responsive biocompatible materials. Specifically, they could be added in the design 
toolbox for achieving better control of tissue response to neural electrode. One possible 
application could be correlating the pH-sensitivity of the PVCL polymers with the tissue 
acidosis phenomenon following the implantation of the electrode. PVCL polymer chains 
will be aggregated or expanded in response to pH variation, thereby providing a potential 
underlying trigger for smart drug delivery. 
4.2 Experimental Section 
4.2.1 Materials  
Diisopropylamine, azobisisobutyronitrile (AIBN), di-tert-butyl dicarbonate and 
N-vinyl-2-caprolactam (VCL) were obtained from Sigma-Aldrich. Tetrahydrofuran 
(THF), n-butyllithium and trifluoroacetic acid (TFA) were obtained from Acros. 
Deuterated dimethyl sulfoxide (d6-DMSO) and chloroform (CDCl3) were obtained from 
Cambridge Isotope Laboratories, Inc. Hexanes and dichloromethane (DCM) were 
purchased from Fisher Scientific. All reagents were used as received unless otherwise 
noted. 
4.2.2 Characterization  
1H-NMR (300 MHz) spectra were recorded on a Varian Mercury 300 NMR 
spectrometer. Fourier transform infrared spectroscopy (FT-IR) was carried out using 
potassium bromide pellets on a Bio-RAD FTS6000 FT-IR spectrometer. Gel permeation 
chromatography (GPC) was performed at room temperature using PL-GPC 50 Plus 
(Polymer Laboratories, Inc.) with a refractive index detector. N, N-Dimethylformamide 
was used as the carrier solvent at a flow rate of 1.0 mL/min. Standard monodisperse 
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polystyrenes (Polymer Laboratories) were used for calibration. Thermogravimetric 
analysis (TGA) was performed on Q-50 (TA Instrument) at a heating rate of 20 °C/min in 
a nitrogen atmosphere. The degree of ionization of the copolymer at various pH values 
was determined from potentiometric titration curves. Polymer solutions (1 mg/mL) were 
titrated with 0.1 mol/L NaOH. pKa was estimated from the titration curve. The degree of 
ionization was then calculated as α = 	 b 5cdefcg, α = [1 / (1 + 10 
(pKa-pH))]. 
4.2.3 Synthesis of carboxylated VCL homopolymer (COOH-PVCL-H)  
Monomer of 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam (TBVCL) was 
synthesized as described previously.[178] TBVCL (1.195 g, 5 mmol), AIBN (0.008 g, 
0.049 mmol) and freshly distilled THF (5 mL) were added into a 50 mL flask, and 
subjected to three freeze-thaw cycles to remove oxygen. Polymerization reaction took 
place at 65 °C for 24 h. The polymer was then precipitated in hexane, redissolved in THF 
and reprecipitated in hexane for purification. The obtained polymer (COOH-PVCL-BOC-
H, 160 mg, 14% yield) was dried in a vacuum oven at 55 °C overnight (Mn = 5,400 
g/mol). The carboxyl groups (-COOH) were recovered by removing the t-BOC protecting 
groups using TFA. Briefly, PVCL-COOH-BOC-H was dissolved in DCM followed by 
the addition of TFA. After reacting for 3 h, the polymer was recovered by solvent 
evaporation and dried in a vacuum oven at 100 °C overnight.  
4.2.4 Synthesis of carboxylated VCL copolymer (COOH-PVCL)  
In a typical procedure (Figure 40), TBVCL (0.478 g, 2 mmol), VCL (2.5 g, 18 
mmol), AIBN (0.049 g, 0.3 mmol) and freshly distilled THF (10 mL) were added into a 
35 mL reaction tube.   
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Figure 40. Synthesis of the monomer 3-(tert-butoxycarbonyl)-N-vinyl-2-caprolactam 
(TBVCL) and partially or fully carboxylated PVCL polymers. Intramolecular hydrogen 
bonding was shown in polymers 3 and 5. 
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The mixture was then subjected to three freeze-thaw cycles to remove oxygen. 
Polymerization reaction took place at 65 °C for 24 h. The polymer was then precipitated 
in hexane for purification. The obtained polymer (COOH-PVCL-BOC) was dried in a 
vacuum oven at 55 °C overnight. The yields were above 80%. The carboxyl groups (-
COOH) were recovered by removing the t-BOC protecting groups using TFA. Briefly, 
COOH-PVCL-BOC was dissolved in DCM followed by the addition of TFA. After 3 h of 
reaction, the polymer (COOH-PVCL) was recovered by solvent evaporation followed by 
precipitation in hexane and dried in a vacuum oven overnight.  
4.2.5 Reactivity study 
A typical experiment is described below. TBVCL (69.73 mg, 0.29 mmol) and VP 
(35.51 mg, 0.32 mmol) were firstly mixed in CDCl3 (0.5 mL), with the initiator AIBN 
(1.5 mg, 0.009 mmol). Pyridine (4.94 mg, 0.06 mmol) was added as an external standard. 
The mixture in CDCl3 was then placed in the NMR spectrometer for the initial spectrum 
collection and frozen in a -20 °C fridge to quench any polymerization at room 
temperature. After reaction in the oil bath at 65 °C for 20 minutes, the NMR tube was 
taken out and quenched in a -20 °C fridge before measurement. Similarly, two other 
NMR tubes with different compositions of TBVCL and VP were prepared and the same 
procedures were followed. The experiments for determining reactivity values of VCL and 
VP were also carried out using the same procedures described above. 
4.2.6 Cloud point measurement  
The transmittance for the aqueous polymer solution was measured with a UV-
visible spectrophotometer (Biomate 5 from Thermospectronic) at 540 nm by following 
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the turbidity of the polymer solution as a function of temperature. Cloud point was 
defined using the heating curve as the temperature at which the transmittance was 50% of 
the value at room temperature. A heating/cooling rate of 0.2 °C/min was used.  
Concentrations of all polymer solutions were 2.5 mg/mL. 
4.2.7 In vitro cytotoxicity study  
In vitro cytotoxicity of the COOH-PVCL copolymer was examined using the 
NIH/3T3 fibroblast cell line. Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (Fetal Clone III, Fisher), 1% L-
glutamine and 1% penicillin/streptomycin. Cells were maintained at 37 °C, 5% CO2 and 
95% relative humidity. Prior to cytotoxicity test, cells were harvested using trypsin–
ethylenediamine tetraacetic acid (EDTA)–PBS solution (0.25% trypsin–0.038% EDTA) 
and diluted to a density of 1 × 105 cells/mL. The cell suspension was added into 96-well 
plates at 100 µL/well, and cells were allowed to attach overnight. Cell culture medium 
was then aspirated and replaced with fresh medium supplemented with COOH-PVCL at 
different concentrations ranging from 0.1 to 10 mg/mL. Cells were incubated overnight 
and polymer cytotoxicity was determined using an MTT assay (Promega, CellTiter 96) 
according to the manufacturer’s instruction. Negative (without COOH-PVCL) and blank 
(without cells) controls were also included. Statistical analysis was conducted using 
Student’s t-test. 
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4.2.8 LBL assembly of COOH-PVCL/PVCL monitored by Quartz crystal 
microgravimetry (QCM)  
QCM measurements were conducted at room temperature using a Q-sense device 
(E4) with a flow cell (Q-Sense AB, Västra Frölunda, Sweden). A gold-coated 5 MHz 
AT-cut crystal was excited at multiple overtones, and the change in the resonance 
frequency was recorded. After deposition of the initial layer of PEI (1.5 mg/mL), the 
chamber was washed with water, after which the solution of COOH-PVCL (0.5 mg/mL, 
pH = 3.0) was introduced into the chamber and allowed to adsorb for 5 min. 
Subsequently, the chamber was washed again with HCl (pH = 3.0) and then filled with 
PVCL solution (0.5 mg/mL, pH =3.0), allowing an adsorption time of 5 min. The 
multilayer film was then assembled by alternating incubations between COOH-PVCL 
and PVCL. 
4.3 Results and Discussion 
4.3.1 Polymer synthesis and characterization  
To integrate additional functionalities such as carboxyl groups while maintaining 
the structural continuity of the caprolactam ring, a derivative of VCL monomer (TBVCL) 
containing a protected carboxylic acid side group was synthesized via nucleophilic 
substitution of VCL at the α–position with tert-butoxycarbonyl group (Figure 40).[179] 
This monomer was previously reported specifically for applications as deep UV 
photoresists for lithography[179-185], and to our best knowledge there is no prior study 
of its potential as smart biomaterials. 
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Chemical structures of TBVCL monomer and its homopolymer were confirmed 
with 1H-NMR (Figure 41). The characteristic peak of t-BOC at 1.46 ppm was observed in 
the monomer structure (Figure 41a).   Homopolymers of carboxylic acid functionalized 
PVCL (COOH-PVCL-H) were obtained by polymerization of TBVCL followed by TFA 
deprotection. The polymer preparation process was monitored with 1H-NMR by 
following the disappearance of characteristic peaks of the double bond in the monomer 
(Figure 41b, peaks at chemical shifts 4.41-4.57 and 7.29-7.44 ppm) and the absence of 
the t-BOC peaks in COOH-PVCL-H (Figure 41c).  
The TBVCL monomer allowed us to introduce a controllable amount of 
carboxylic acid groups in the VCL polymer pendent chains to acquire pH-sensitivity, 
using simple free radical copolymerization of VCL and TBVCL. As TBVCL bears close 
structural resemblance to that of VCL, it is expected that the reactivities of these two 
monomers will be similar comparing to that between VCL and methacrylates/acrylates, 
thus allowing for easier control of the copolymer compositions. Based on the results of 
1H-NMR (Figure 42a, peaks 1 and 4), a molar feed ratio of 9 : 1 VCL : TBVCL resulted 
in a composition of 5.92:1 of the two monomers in the final copolymer (equivalent to 
14.4 mol % TBVCL). This compositional drift is significantly lower than that reported in 
copolymerization of VCL with MAA, where a 9:1 VCL : MAA molar feed ratio yielded a 
1:1 ratio of VCL to MAA in the copolymer (50 mol % MAA).[186] It indicates that: (1) 
the disparity of reactivity between VCL and its functional analogue TBVCL is much less 
than that between VCL and MAA;  
  
 Figure 41. 1H-NMR spectra of (a) monomer TBVCL in CDCl
homopolymer COOH-PVCL
COOH-PVCL-H in d6-DMSO.
a 
c 
b 
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Figure 42. 1H-NMR spectra of (a) protected copolymer COOH
deprotected COOH-PVCL14, (c) protected copolymer COOH
deprotected COOH-PVCL9. CDCl
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and (2) TBVCL is more reactive than VCL, as a higher than theoretical percentage (10 
mol %) of TBVCL was incorporated into the copolymer. The latter holds significance on 
its own, as this could potentially enable further development of functional copolymers 
containing thermo-sensitive VCL structures. A detailed study to determine the reactivity 
ratios of TBVCL with VCL is described later.  
In addition to 1H-NMR, the copolymer composition was further confirmed by 
TGA. As shown in Figure 43a, homopolymer of TBVCL (COOH-PVCL-BOC-H) started 
to lose weight at 203 °C, characteristic of the spontaneous thermolysis of the t-BOC 
groups into carbon dioxide (CO2) and isobutylene (C4H8). At 400 °C, a typical mass loss 
from the PVCL structure was observed. The copolymer (COOH-PVCL-BOC14) also 
possessed the above two regions of mass loss (Figure 43b), and the percentage of t-BOC 
loss was used to calculate molar ratio of TBVCL in the copolymer as 13.6 mol %, which 
is comparable with the NMR result.  
The chemical structures of the homopolymer and copolymers were also confirmed 
by IR spectra (Figure 44). The characteristic band at 1630 cm-1 corresponding to the C=C 
stretching of the vinyl group in the monomer TBVCL (Figure 44a) disappeared in all 
polymer structures. The strong absorbance peak around 1637 cm-1 in the monomer and all 
the polymers are assigned to the C=O stretching of the amide carbonyl group. The peak 
originating from the ester C=O stretching in t-BOC around 1735 cm-1 was observed in 
polymers containing t-BOC groups (COOH-PVCL-BOC-H (Figure 44b) and COOH-
PVCL-BOC (Figure 44d)).  
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Figure 43. TGA spectra of protected TBVCL homopolymer COOH-PVCL-BOC-H (a), 
protected copolymers COOH-PVCL-BOC14 (b) and COOH-PVCL-BOC9 (c). 
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Figure 44. IR spectra of (a) monomer TBVCL, (b) protected homopolymer COOH-
PVCL-BOC-H, (c) deprotected homopolymer COOH-PVCL-H, (d) protected copolymer 
COOH-PVCL-BOC14, and (e) deprotected copolymer COOH-PVCL14. 
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Broad peaks from 2200 to 3600 cm-1 were assigned to the -OH stretching in the -COOH 
groups of the deprotected homopolymer COOH-PVCL-H (Figure 44c) and copolymer 
COOH-PVCL (Figure 44e). 
4.3.2 LCST behaviors of COOH-PVCLs 
The key rationale of introducing carboxylic acid groups in the VCL polymer 
structure is to modulate its thermo-sensitivity with pH. Transmittance at 540 nm of the 
carboxylated copolymer solutions at different pH values was studied using a UV-vis 
 spectrometer for cloud point (Tc) measurements. As summarized in , PVCL 
homopolymer and two PVCL copolymers with comparable molecular weights but 
different amounts of carboxylic acid groups (COOH-PVCL9 and COOH-PVCL14) were 
prepared to specifically study the carboxylic acid groups and compositional effects on the 
thermo-sensitive properties. The molecular weights (Mn) for PVCL, COOH-PVCL-9 and 
COOH-PVCL14 were 3100, 2600, 2600 g/mol respectively. It is important to maintain 
the molecular weights of these polymers consistent as studies have shown that the LCST 
of PVCL is also dependent on molecular weight.[187] Generally, as the molecular weight 
of PVCL increases, its LCST will decrease.  
Figure 45 shows that not only the copolymers retained thermo-sensitivity of 
PVCL, but its phase transition temperature can also be varied as a function of solution pH 
by modulating the amount of carboxylic acid groups in the copolymer. Specifically, cloud 
point of COOH-PVCL9 increased from 35 °C to 44 °C as the pH of solution changed 
from 2 to 7.4 (Figure 45a).  
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Table 3. Molecular weight and compositional data of PVCL containing polymers 
 
polymer 
TBVCL amount (mol %) Mn 
(g/mol) Mw/Mn in feed in polymer 
PVCL - - - 3,100 3.06 
COOH-PVCL9 2.5 8.9a 7.4b 2,600 2.67 
COOH-PVCL14 10 13.6a 14.4b 2,600 2.76 
 
a Estimated from TGA. b Estimated from 1H-NMR. 
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Figure 45. Phase transition profiles of 2.5 mg/mL of (a) COOH-PVCL9 and (b) COOH-
PVCL14 in 0.1 M phosphate buffered saline at different pH values. (c) Cloud points (Tc) 
of various COOH-PVCLs at different pH values. The dash line represents the Tc of 
PVCL homopolymer at pH 7.4. (d) pH vs degree of ionization for COOH-PVCLs at room 
temperature. 
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When the amount of carboxylated VCL increased to 14.4 mol %, a broader range of 
cloud points was observed (Figure 45b), spanning from 29 °C to 64 °C as the solution pH 
increased from 2 to 7.4. In addition, the cooling curves (represented by open symbols in 
Figure 45a and b) overlapped well with the heating curves, demonstrating good 
reversibility of the thermo-responsive PVCL copolymers with little thermo-hysteresis. It 
can also be inferred from the thermo-hysteresis results that the positions of the spinodal 
curve and binodal curve for the PVCL copolymer will be very close to each other on its 
phase diagram, if it were constructed experimentally.  
The observed pH-dependent behavior of the PVCL copolymers can be explained 
by the hydrophilic/hydrophobic balance between the thermo-dependent hydrophobic 
lactam unit and the ionizable –COOH groups. Based on the titration curves (d) 
the pKa values of COOH-PVCL9 and COOH-PVCL14 were determined to be 3.1 and 
3.2, respectively. Thus, at pH 2 the carboxylic acid groups of the copolymers are partially 
deprotonated, and at pH 7.4 fully deprotonated. Compared with homopolymer PVCL, the 
carboxylic acid groups could either decrease or increase Tc of the copolymer, depending 
on whether carboxylate groups (i.e. protonated form of carboxylic acid, -COOH) or 
deprotonated carboxylic acid groups (-COO-) dominated in the polymer structure. On one 
hand, carboxylate groups lead to more hydrophobic structures from the likely 
intramolecular hydrogen bonding (shown in Figure 40), resulting in a lower Tc. On the 
other hand, deprotonated carboxylic acid groups, which increase hydrophilicity of the 
polymer, would require a higher Tc to compensate for the enhanced hydrophilicity.[87, 
188] As shown in Figure 45c, Tc of COOH-PVCL9 at pH 4 was the same as PVCL 
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homopolymer, suggesting that the hydrophilic effect of the ionized -COO- groups 
balanced the hydrophobic effect of the protonated –COOH groups at that pH. However, 
Tc of COOH-PVCL14 at the same pH was 7 °C lower. Considering that COOH-PVCL14 
has a slightly higher pKa than COOH-PVCL9, I expect that at pH 4 less carboxylic acid 
groups are ionized/deprotonated for COOH-PVCL14, leading to a higher percentage of 
hydrophobic –COOH groups and therefore a lower Tc.  
Another observation of the thermo-sensitivity studies is that as pH increased, the 
Tc for both copolymers increased as well, since more –COOH groups were ionizing and 
the polymer became more hydrophilic. A more dramatic increase was observed for 
COOH-PVCL14 due to the higher molar percentage of carboxyl groups. Although only 
two copolymer compositions were studied here, I can postulate that a further increase of 
the molar percentage of TBVCL in the copolymer will likely lead to a wider range of Tc 
as a function of pH. I have observed that for the deprotected homopolymer of TBVCL 
(COOH-PVCL-H), its solution at pH 4 remained cloudy even at 4 °C; and at pH 5, the 
solution remained clear until the temperature reached 95 °C (data not shown). These 
observations can be explained by the very high concentration of –COOH groups, which 
both further improve hydrophobicity at low pH and hydrophilicity at high pH. 
Additionally, the homopolymer COOH-PVCL-H was not soluble in pure water due to 
strong prevalence of intra- and intermolecular hydrogen bonding. I also examined the 
phase behavior of homopolymer PVCL at pH 2 and 5, and the corresponding Tc values 
were the same as that at pH 7.4, indicating the thermo-responsive behavior of 
homopolymer PVCL lacks pH sensitivity. 
 127 
 
It is also worth noting the sensitivity in the phase transition behavior of the copolymers. 
As shown in , temperature sensitivity was obtained by measuring the temperature range 
corresponding to transmittance change from 90% to 10%. Unlike other reported pH-
sensitive thermo-responsive polymers,[87, 177] where sharp phase transition is limited to 
those with a small amount of acidic component (i.e. less than 3-5 mol %) at certain pH 
values (pH 5.0 – 6.5), our system demonstrated that even at a high 14 mol % of 
functionalization, these copolymers responded sharply to both pH (from 2.0 to 7.4) and 
temperature the same way as the PVCL homopolymer (Figure 46). Such improvement 
could be attributed to the well maintained continuity of the thermo-dependent lactam 
groups in the polymer structure, allowing sufficient polymer aggregation even in the 
presence of high amounts of ionic groups. The importance of sharp phase transition is 
evident as it will boost the sensitivity of intended biomedical applications of these smart 
biomaterials, such as molecular switching and drug delivery. 
4.3.3 Cytotoxicity study of COOH-PVCL 
It is well known that PNVP has been widely used in biomedical applications.[68] 
Considering the structural similarity between PVCL and PNVP, PVCL based polymers 
have also been proposed for biological applications. It was shown that PVCL 
homopolymers were well tolerated at various concentrations (0.1-10.0 mg/ml).[189] To 
study how the incorporation of carboxyl groups affects biocompatibility of PVCL, I used 
fibroblast cells to measure cytotoxicity of COOH-PVCL copolymers. As shown in Figure 
47, COOH-PVCL was non-toxic to the cells at concentrations up to 2 mg/mL. 
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Figure 46. Influence of chemical compositions on the temperature sensitivity of phase 
transition. Top and bottom bars of each data point represent the temperature at 90% and 
10% of the solution transmittance, respectively. 
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Figure 47. NIH/3T3 fibroblast cells viability after overnight incubation with different 
concentrations of COOH-PVCL copolymers. Cells without polymer treatment served as a 
negative control. Data shown are average ± STD (n = 3). 
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Upon further increase of the polymer concentration to 10 mg/mL, the cell 
viability significantly decreased (p < 0.01) as shown by the reduction in the MTT assay 
absorbance, an indication of decrease of mitochondrial activity in cells. It is likely that 
higher concentrations of the carboxylated polymer lead to acidification of the culture 
medium indicated by the color change of medium, thus affecting cell growth. These 
results suggest that the synthesized functional PVCL copolymer is biocompatible 
depending on the concentrations applied.  
Although this new biocompatible PVCL-derived dual-responsive polymers can 
have various biomedical applications where the use of smart biomaterials are desirable, I 
am particularly interested in its use for drug delivery from the surface of biomedical 
implants. As the LCST of this PVCL copolymer at pH 5.0, a pH condition featured in 
inflamed tissues,[34, 88, 190] is drastically different from that at normal 
physiologicaltissue of pH 7.4, I could use such characteristics to engineer multilayers on 
the surface of biomedical implants and achieve inflammation triggered drug delivery. The 
idea is to assemble multilayers with this dual-responsive PVCL copolymer as one of the 
components, and upon inflammation induced tissue acidosis, it leads to the molecular 
conformational changes due to its associated reduction of LCST, which will subsequently 
change the properties of the multilayers and enable drug release. With this biocompatible 
dual-responsive polymer, I hope to improve the correlation and control between drug 
treatment and the extent of tissue response to biomedical implants in future studies.  
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4.3.4 Reactivity study 
In order to expand the application of TBVCL, copolymerization with other 
biomaterials-related monomers is a good option. The reactivity values of these monomer 
pairs are therefore of our interest. There are many mathematical approaches to calculate 
reactivity values. Among these methods, Kelen and Tudos (K-T) method is chosen for 
my study due to its relative simplicity and popularity. Depending on the molecular 
structures, different experimental techniques could be employed including TGA, FTIR, 
UV, NMR, etc. The common objective for these experiments is to obtain compositions of 
the two monomers before and after composition. In my case, NMR was used due to the 
distinctive monomer peaks in the spectra. To test my method, two commercially available 
monomers (VCL and VP) were firstly studied.Small amounts of VCL and VP were firstly 
mixed in CDCl3 at a predetermined feeding ratio. Pyridine was added as an external 
standard. In a quantitative NMR study, internal standard, which means a peak belonging 
to one of the reactants, is preferred if possible. However, in this case, there is no such 
suitable internal standard peak. Therefore, an external standard is necessary and the 
choice is based on the following conditions. Firstly, the standard peak needs to be clearly 
distinguished from other peaks. Secondly, the standard chemical cannot react with 
monomers. Thirdly, the chemical should be stable at the polymerization temperature, 65 
°C. Based on the above limits and the spectral information from VCL and VP, one 
possible region of standard peak was identified at the lower chemical shift. Common 
solvents were screened and pyridine was finally chosen as the external standard satisfying 
the above requirements.  
 132 
 
The mixture in CDCl3 was firstly placed in the NMR spectrometer for the initial 
spectrum collection. After reaction in the oil bath at 65 °C for 20 minutes, the NMR tube 
was taken out and quenched in a -20 °C fridge before measurement. Similarly, two other 
NMR tubes with different compositions were prepared and the same procedures were 
followed. The above data (the NMR spectra are shown in Appendix Figure 53-64) were 
plotted according to the widely used linear graphic K-T method.[191] The above 
procedures are also summarized in Figure 48. And the reactivity values were obtained 
from the slope and intercept. The K-T method is based on the following equation: 
 h = iQ + jkl m −
j
k  13 
where r1, r2 are the reactivity values for monomers. Other parameters are defined 
by the following equations: 
 n = opo 14 
 	q = ropro 15 
 
 s = t

u   16 
 G = t5uvu 	  17 
 h = wkbx	  18 
 m = xkbx  19 
  
  
 
 
 
 
 
 
 
 
 
 
Figure 48. Schematic illustration for reactivity valu
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where M1, M2 are the molar amount of the two monomers at the starting point t. 
dM1, dM2 are the amount of  monomers reacted during polymerization period. α is an 
arbitrary positive constant. A feasible choice is:  
 y = zs{so   20 
where Fm and FM are the lowest and highest values of F, respectively. 
There is one constraint on the K-T method. It requires the monomer conversion to 
be rather low (< 20%). In this case, I kept the conversion below 15%. Detailed 
calculation was carried out and shown in the Appendix (Table 4 and Table 5). 
The reactivity values for VP and VCL are calculated to be 4.5 and 0.8 
respectively. These data were reported previously in another handbook as 2.8 and 1.7 
respectively. My results are consistent with the reference in that the value for VP is larger 
than VCL. However, the difference could be attributed to the inherent variance between 
different methods for determining reactivity values. 
After the experiment for monomer pair of VP and VCL, I proceed to VP and 
TBVCL. Using the same method, the reactivity values for VP and TBVCL are 
determined as 0.7 and 2.1 respectively.  
Attempts have also been made to study VCL and TBVCL. However, this method 
did not work because no distinctive peaks in NMR spectra can be identified for 
calculation due to the structural similarity between VCL and TBVCL. Even though direct 
derivation of the values cannot be obtained, an indirectly approach to compare the 
reactivity of VCL and TBVCL is possible and described as followed.  
 135 
 
From the above results, the reactivity values for VP and TBVCL are 0.7 and 2.1 
respectively, leading to a conclusion that TBVCL is more reactive than VP. The 
reactivity values for VP and VCL are calculated as 4.5 and 0.8 using the same method. It 
is concluded that for the order of reactivity, TBVCL > VP and VP > VCL. Therefore, I 
inferred that TBVCL is more reactive than VCL. This conclusion also coincides with the 
composition of the copolymer of TBVCL and VCL. For example, when VCL and 
TBVCL were added at 9:1 molar ratio, the resulting polymer has a molar composition of 
6:1. It should be noted that it is still possible to determine the reactivity values of VCL 
and TBVCL by other methods such as TGA. Such an approach was not pursued further 
due to the limitation of monomer availability. 
4.3.5 LBL coating consisting of COOH-PVCL 
The synthesized COOH-PVCL is used as the hydrogen bonding donor component 
in the LBL process. To simply prove the feasibility of this approach, PVCL was 
employed as the hydrogen boding acceptor, which has been demonstrated by other 
researchers to be able to form LBL films with another polymeric component. QCM was 
utilized to monitor the layer assembly process. As shown in Figure 49, after deposition of 
the base layer of PEI, COOH-PVCL could be adsorbed onto the PEI layer. However, 
further alternately flowing PVCL and COOH-PVCL could not deposit any appreciable 
amounts of polymers onto the Au surface. The underlying reasons could be the low 
density of hydrogen bonding donor groups, resulted from low molecular weight of 
COOH-PVCL or the small amount of carboxylic acid groups available on the polymer 
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chain. The weak hydrogen bonding interaction from the current polymer pair did not 
provide sufficient force for stable multilayers formation. 
Even though the above exploratory experiment did not result in successful 
multilayer deposition, further improvements could be concentrated on increasing the 
polymer molecular weight or percentage of COOH groups to realize biocompatible LBL 
coatings. 
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Figure 49. A QCM plot showing the change in frequency (proportional to adsorbed mass) 
as a function of the adsorption and build-up of multilayers of COOH-PVCL/PVCL. 
  
PEI COOH-PVCL PVCL COOH-PVCL PVCL 
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4.4 Conclusions 
I have successfully integrated pH and thermo-sensitivity for PVCL polymers by 
maintaining the structural continuity of the caprolactam ring while introducing carboxyl 
groups via copolymerization with TBVCL, a functional derivative of VCL. The cloud 
point of the copolymer can be tuned from 29 °C to 64 °C by changes of solution pH from 
2 to 7.4. Cytotoxicity studies of the copolymer on NIH/3T3 fibroblasts showed good 
biocompatibility up to a polymer concentration of 2 mg/mL. The high content of the 
functional carboxyl groups in the copolymer will also enable further conjugation of 
bioactive molecules for broader applications in biotechnology and drug delivery. 
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Chapter 5 
Summary and Future Work 
A mutli-functional approach to combat the tissue response from brain to MEAs 
was designed. Anti-inflammatory and anti-oxidant therapeutics were employed to achieve 
the objective. Individual polymer therapeutic was developed and the their properties were 
fully characterized. The polymers structure and the therapeutic loading capacity are 
controllable. The in vitro cell studies showed that they maintained the therapeutic effects. 
These polymeric therapeutics were further successfully incorporated onto the silicon 
substrate, as the main materials for the neural implants. Also some key design features 
were demonstrated such as the pH-responsive release of anti-inflammatory prodrug, 
dissociable coatings in the brain environment, and complex coatings structure consisting 
stable and unstable components. Furthermore, a smart polymer responsive to pH and 
temperature was synthesized and characterized, with the potential to be incorporated in 
the complex design to realize advanced therapeutic delivery system.  
The specific conclusions in this dissertation were listed below: 
1. A poly(N-vinyl pyrrolidone) based glucocorticoid-polymer prodrug was 
synthesized by conjugating prednisolone to functionalized PNVP via a hydrazone 
linkage. 
2. pH sensitivity of drug release from the poly(N-vinyl pyrrolidone) based 
prodrug was observed under conditions mimicking inflammation-induced tissue acidosis, 
as hydrolysis of the hydrazone linkage was enhanced under acidic pH.  
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3. Poly(N-vinyl pyrrolidone) based prodrug and its released products 
demonstrated good biocompatibility with neurons. Neural culture showed that both the 
prodrug and its precursor polymer were non-toxic to neurons and did not alter the ability 
of neurons to maintain neurite extensions, reassuring further application of this prodrug 
to mitigate inflammation at the neural interface.  
4. Bioactivity of the poly(N-vinyl pyrrolidone) based prodrug and its 
released free drug were studied with RAW264.7 macrophages in vitro, where inhibition 
of nitric oxide production was observed, suggesting the desired anti-inflammatory effect.  
5. Poly(N-vinyl pyrrolidone) based prodrug was also compatible with the 
hydrogen bond-driven LBL assembly technique. Multilayers of poly(acrylic 
acid)/prodrug were successfully deposited onto silicon substrates and quartz plates. The 
layers were destructible when incubated in physiological pH, which could be beneficial 
for neural electrodes.  
6. Poly(N-vinyl pyrrolidone) based prodrug can serve as a promising and 
versatile drug delivery system. It can be easily applied to neural electrodes without 
compromising the electrical property of the implant, and can potentially realize tissue 
response-regulated drug release based on tissue acidosis. This system allows localized 
pharmacological interventions that deliver anti-inflammatory drugs based on the extent of 
inflammation without interfering with the electrical properties of the neural electrodes. 
7. Compositionally controllable antioxidant polymeric therapeutics PVTs 
were prepared by copolymerizing monomers of triethylene glycol methyl acrylate 
(TEGMA) and α-tocopheryl acrylate (VeAc). In contrast to the poor water solubility of 
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Ve, solubility of the PVT prodrug in water can reach as high as 3.1 mg/mL (equivalent to 
500 µM Ve) by tuning the copolymer composition.  
8. The PVT prodrug was non-cytotoxic toward A172 human astrocytes. 
Furthermore, PVT was able to protect astrocytes against oxidative stress exerted by 
hydrogen peroxide in vitro. Using a free radical scavenging assay, the protection 
mechanism was suggested to be attributed to the hydrolysis of the labile ester linkage and 
release of the active Ve.  
9. Multilayers containing PVT with tunable stability at physiological 
condition could be achieved simply by engineering the layer composition. PVT was 
successfully deposited on silicon (Si) substrates with poly(acrylic acid) (PAA) or tannic 
acid (TA) using the LBL technique mediated by hydrogen bonding. Ellipsometry and 
quartz crystal microbalance (QCM) data showed that the multilayers of PAA/PVT were 
destructible at physiological pH. In contrast, multilayers of TA/PVT were stable.  
10. Functionalized temperature- and pH-sensitive poly(N-vinyl-2-
caprolactam) polymers were prepared by copolymerizing monomers of VCL and a VCL 
derivative, TBVCL..  
11. Sharp, complete and reversible phase transitions of the copolymers with 
little hysteresis were shown to be pH-dependent, with cloud points ranging from 35 °C to 
44 °C for COOH-PVCL9, and 29 °C to 64 °C for COOH-PVCL14, upon pH change from 
2.0 to 7.4.  
12. Biocompatibility cytotoxicity assay demonstrates that the functionalized 
PVCL copolymers were biocompatible with NIH/3T3 up to 2 mg/mL.  
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13. The functionalized PVCL copolymers hold potential to be used for drug 
delivery from the surface of biomedical implants. The idea is to assemble multilayers 
with this dual-responsive PVCL copolymer as one of the components, and upon 
inflammation induced tissue acidosis, it leads to the molecular conformational changes 
due to its associated reduction of LCST, which will subsequently change the properties of 
the multilayers and enable drug release.  
Based on above conclusions in this dissertation, future work is proposed, 
including: 
1. In vitro study of anti-inflammatory and anti-oxidant prodrugs on primary 
cells such as brain derived microglia, astrocytes, and neurons. 
2. Validation of the efficacy of different films in improving the 
biocompatibility of the neural implant in a rat model. These films will include LBL 
coatings with either anti-inflammatory or anti-oxidant prodrug. Furthermore, possible 
synergistic effect will be examined when the film contains both prodrugs. 
3. Modulation of the molecular weight and composition of functional 
poly(N-vinyl-2-caprolactam), and incorporation of these polymers in multilayered films 
as a smart drug delivery platform responsive to temperature and pH, toward neural 
implant applications.  
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 APPENDIX 
 
 
Figure 50. Fluorescent images and intensity in the diffused region of the fluorescent prodrug 
analog.  
 156 
 
Table 4. Calculation for the reactivity of VCL and VP. 
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Table 5. Calculation for the reactivity of TBVCL and VP. 
 
 
 158 
 
 
Figure 51. K-T plot for the reactivity study of VCL and VP. 
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Figure 53. NMR spectra of VCL and VP at a molar feeding ratio of 0.5, before 
polymerization. 
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Figure 54. NMR spectra of VCL and VP at molar feeding ratio of 0.5, after 
polymerization at 65 °C for 20 minutes. 
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Figure 55. NMR spectra of VCL and VP at molar feeding ratio of 1, before 
polymerization 
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Figure 56. NMR spectra of VCL and VP at molar feeding ratio of 1, after polymerization 
at 65 °C for 20 minutes. 
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Figure 57. NMR spectra of VCL and VP at molar feeding ratio of 2, before 
polymerization 
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Figure 58. NMR spectra of VCL and VP at molar feeding ratio of 2, after polymerization 
at 65 °C for 20 minutes. 
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Figure 59. NMR spectra of TBVCL and VP at molar feeding ratio of 0.5, before 
polymerization. 
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Figure 60. NMR spectra of TBVCL and VP at molar feeding ratio of 0.5, after 
polymerization at 65 °C for 20 minutes. 
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Figure 61. NMR spectra of TBVCL and VP at molar feeding ratio of 1, before 
polymerization. 
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Figure 62. NMR spectra of TBVCL and VP at molar feeding ratio of 1, after 
polymerization at 65 °C for 20 minutes. 
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Figure 63. NMR spectra of TBVCL and VP at molar feeding ratio of 2, before 
polymerization 
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Figure 64. NMR spectra of TBVCL and VP at molar feeding ratio of 2, after 
polymerization at 65 °C for 20 minutes. 
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